ZA200404959B - Quinazolinone derivatives and their use as CB agonists - Google Patents
Quinazolinone derivatives and their use as CB agonists Download PDFInfo
- Publication number
- ZA200404959B ZA200404959B ZA200404959A ZA200404959A ZA200404959B ZA 200404959 B ZA200404959 B ZA 200404959B ZA 200404959 A ZA200404959 A ZA 200404959A ZA 200404959 A ZA200404959 A ZA 200404959A ZA 200404959 B ZA200404959 B ZA 200404959B
- Authority
- ZA
- South Africa
- Prior art keywords
- caalkyl
- compound
- alkylene
- formula
- hydrogen
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title description 10
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 117
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 239000001257 hydrogen Substances 0.000 claims description 60
- 229910052799 carbon Inorganic materials 0.000 claims description 43
- 150000003839 salts Chemical group 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 33
- 239000012458 free base Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000001931 aliphatic group Chemical group 0.000 claims description 25
- 125000006413 ring segment Chemical group 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 19
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims description 16
- 108050007331 Cannabinoid receptor Proteins 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 15
- 208000010412 Glaucoma Diseases 0.000 claims description 12
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 229940088679 drug related substance Drugs 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 210000001328 optic nerve Anatomy 0.000 claims description 9
- -1 Cy-C Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 208000000094 Chronic Pain Diseases 0.000 claims description 6
- 208000022873 Ocular disease Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 5
- 206010067013 Normal tension glaucoma Diseases 0.000 claims description 5
- 208000004760 Tenosynovitis Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 201000002978 low tension glaucoma Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 210000001525 retina Anatomy 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- UFXNCSRAJJJLJN-UHFFFAOYSA-N ethyl 2-(ethylcarbamoyloxymethyl)-5,7-dimethyl-3-[2-(methylsulfamoyl)phenyl]-4-oxoquinazoline-6-carboxylate Chemical compound CCNC(=O)OCC1=NC2=CC(C)=C(C(=O)OCC)C(C)=C2C(=O)N1C1=CC=CC=C1S(=O)(=O)NC UFXNCSRAJJJLJN-UHFFFAOYSA-N 0.000 claims description 4
- 102100028644 Tenascin-R Human genes 0.000 claims description 2
- 108010020387 tenascin R Proteins 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- PMBUDILHPXTDNY-UHFFFAOYSA-N ethyl 2-(2-hydroxyethylcarbamoyloxymethyl)-5,7-dimethyl-3-[2-(methylsulfamoyl)phenyl]-4-oxoquinazoline-6-carboxylate Chemical compound O=C1C2=C(C)C(C(=O)OCC)=C(C)C=C2N=C(COC(=O)NCCO)N1C1=CC=CC=C1S(=O)(=O)NC PMBUDILHPXTDNY-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000001525 receptor binding assay Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 5
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 5
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 229930003827 cannabinoid Natural products 0.000 description 5
- 239000003557 cannabinoid Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000035154 Hyperesthesia Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- FHUSFHDCSMXIBP-UHFFFAOYSA-N 4-o-ethyl 1-o,2-o-dimethyl 3,5-dimethylbenzene-1,2,4-tricarboxylate Chemical compound CCOC(=O)C1=C(C)C=C(C(=O)OC)C(C(=O)OC)=C1C FHUSFHDCSMXIBP-UHFFFAOYSA-N 0.000 description 3
- GNGNMHQUAACNST-UHFFFAOYSA-N 6-amino-3-ethoxycarbonyl-2,4-dimethylbenzoic acid Chemical compound CCOC(=O)C1=C(C)C=C(N)C(C(O)=O)=C1C GNGNMHQUAACNST-UHFFFAOYSA-N 0.000 description 3
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 3
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 3
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- OFBXYQLWNDBECP-UHFFFAOYSA-N 1-o-ethyl 3-o-methyl 4-amino-2,6-dimethylbenzene-1,3-dicarboxylate Chemical compound CCOC(=O)C1=C(C)C=C(N)C(C(=O)OC)=C1C OFBXYQLWNDBECP-UHFFFAOYSA-N 0.000 description 2
- WUFSMRKPYVAIFZ-UHFFFAOYSA-N 2-(hydroxymethyl)-5,7-dimethyl-3-[2-(methylsulfamoyl)phenyl]-4-oxoquinazoline-6-carboxylic acid Chemical compound CNS(=O)(=O)C1=CC=CC=C1N1C(=O)C2=C(C)C(C(O)=O)=C(C)C=C2N=C1CO WUFSMRKPYVAIFZ-UHFFFAOYSA-N 0.000 description 2
- SSEZSHJJNNLTQI-UHFFFAOYSA-N 2-amino-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1N SSEZSHJJNNLTQI-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- IZIUWDBVKJOXMF-UHFFFAOYSA-N 3-ethoxycarbonyl-2,4-dimethyl-6-[(2-phenylmethoxyacetyl)amino]benzoic acid Chemical compound OC(=O)C1=C(C)C(C(=O)OCC)=C(C)C=C1NC(=O)COCC1=CC=CC=C1 IZIUWDBVKJOXMF-UHFFFAOYSA-N 0.000 description 2
- WJDNHFSUJLHTAB-UHFFFAOYSA-N 3-ethoxycarbonyl-6-[(4-ethoxy-4-oxobutanoyl)amino]-2,4-dimethylbenzoic acid Chemical compound CCOC(=O)CCC(=O)NC1=CC(C)=C(C(=O)OCC)C(C)=C1C(O)=O WJDNHFSUJLHTAB-UHFFFAOYSA-N 0.000 description 2
- HVKHPNRUJWGELU-UHFFFAOYSA-N 3-o-ethyl 1-o-methyl 2,4-dimethyl-6-[(2-methylpropan-2-yl)oxycarbonylamino]benzene-1,3-dicarboxylate Chemical compound CCOC(=O)C1=C(C)C=C(NC(=O)OC(C)(C)C)C(C(=O)OC)=C1C HVKHPNRUJWGELU-UHFFFAOYSA-N 0.000 description 2
- RTKLEOHYDUERAO-UHFFFAOYSA-N 4-ethoxycarbonyl-2-methoxycarbonyl-3,5-dimethylbenzoic acid Chemical compound CCOC(=O)C1=C(C)C=C(C(O)=O)C(C(=O)OC)=C1C RTKLEOHYDUERAO-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 2
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- FBPWNVQUVXSXKS-UHFFFAOYSA-N ethyl 2,4-dimethyl-6-oxopyran-3-carboxylate Chemical compound CCOC(=O)C=1C(C)=CC(=O)OC=1C FBPWNVQUVXSXKS-UHFFFAOYSA-N 0.000 description 2
- ZYKXHQPBAKWKDB-UHFFFAOYSA-N ethyl 3-(2-chlorophenyl)-2-[3-(ethylamino)-3-oxopropyl]-5,7-dimethyl-4-oxoquinazoline-6-carboxylate Chemical compound CCNC(=O)CCC1=NC2=CC(C)=C(C(=O)OCC)C(C)=C2C(=O)N1C1=CC=CC=C1Cl ZYKXHQPBAKWKDB-UHFFFAOYSA-N 0.000 description 2
- XSGIMQYPEVHEGE-UHFFFAOYSA-N ethyl 5,7-dimethyl-3-[2-(methylsulfamoyl)phenyl]-4-oxo-2-(phenylmethoxymethyl)quinazoline-6-carboxylate Chemical compound C=1C=CC=C(S(=O)(=O)NC)C=1N1C(=O)C2=C(C)C(C(=O)OCC)=C(C)C=C2N=C1COCC1=CC=CC=C1 XSGIMQYPEVHEGE-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DLJPYODODWSDBI-UHFFFAOYSA-N n-methyl-2-nitrobenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O DLJPYODODWSDBI-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007655 standard test method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- PRZWBGYJMNFKBT-UHFFFAOYSA-N yttrium Chemical compound [Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y][Y] PRZWBGYJMNFKBT-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- XFKCVVFQGHCLIP-UHFFFAOYSA-N 2-ethylbutanedioyl dichloride Chemical compound CCC(C(Cl)=O)CC(Cl)=O XFKCVVFQGHCLIP-UHFFFAOYSA-N 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
- QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- IZTJATBUPYEGKW-UHFFFAOYSA-N 3-[3-(2-chlorophenyl)-6-ethoxycarbonyl-5,7-dimethyl-4-oxoquinazolin-2-yl]propanoic acid Chemical compound O=C1C2=C(C)C(C(=O)OCC)=C(C)C=C2N=C(CCC(O)=O)N1C1=CC=CC=C1Cl IZTJATBUPYEGKW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- DJXRKPDJIRKLAK-UHFFFAOYSA-N 4-ethoxycarbonyl-3,5-dimethylphthalic acid Chemical compound CCOC(=O)C1=C(C)C=C(C(O)=O)C(C(O)=O)=C1C DJXRKPDJIRKLAK-UHFFFAOYSA-N 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 230000010737 Cannabinoid Receptor Interactions Effects 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940025141 anafranil Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 239000006067 antibiotic powder Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-N butynedioic acid Chemical compound OC(=O)C#CC(O)=O YTIVTFGABIZHHX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- KHPXDOBGSHNKDM-UHFFFAOYSA-N ethyl 2-(hydroxymethyl)-5,7-dimethyl-3-[2-(methylsulfamoyl)phenyl]-4-oxoquinazoline-6-carboxylate Chemical compound O=C1C2=C(C)C(C(=O)OCC)=C(C)C=C2N=C(CO)N1C1=CC=CC=C1S(=O)(=O)NC KHPXDOBGSHNKDM-UHFFFAOYSA-N 0.000 description 1
- IPDXZSCXRFEXFK-UHFFFAOYSA-N ethyl 3-(2-chlorophenyl)-2-(3-ethoxy-3-oxopropyl)-5,7-dimethyl-4-oxoquinazoline-6-carboxylate Chemical compound CCOC(=O)CCC1=NC2=CC(C)=C(C(=O)OCC)C(C)=C2C(=O)N1C1=CC=CC=C1Cl IPDXZSCXRFEXFK-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 102000056693 human CNR2 Human genes 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- 229940055692 pamelor Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- YPZMSENPJMICIF-UHFFFAOYSA-N propyl 2-(2-hydroxyethylcarbamoyloxymethyl)-5,7-dimethyl-3-[2-(methylsulfamoyl)phenyl]-4-oxoquinazoline-6-carboxylate Chemical compound O=C1C2=C(C)C(C(=O)OCCC)=C(C)C=C2N=C(COC(=O)NCCO)N1C1=CC=CC=C1S(=O)(=O)NC YPZMSENPJMICIF-UHFFFAOYSA-N 0.000 description 1
- OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical compound [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229940118176 surmontil Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 229940035276 tofranil-pm Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940045977 vivactil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Description
Quinazolinone derivatives and their use as CB agonists
The present invention relates to novel quinazolinone derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
More particularly the present invention provides in a first aspect, a compound of formula
R? , R! R® 0 R
RU EEE ne R®
R® A 0 wherein
R'R?, R®, R* and R® independently are hydrogen; halogen; C-Csalkyl; C-Caalkenyl; Cs-
Cicycloalkyl; C3-CcycloalkylCy-Caalkyl; C,-C,alkoxyCi-C,alkyl; C4-Caalkyicarboxy; hydroxyC4-C,alkoxyC,-Caalkyl; hydroxy; hydroxyCy-Caalkyl; phenyiCs-Csalkyl which is optionally substituted by hydroxy, Cy-C.alkoxy, carboxy, C,-C.alkoxycarbonylC;-Csalkyl, C4-
C.alkoxycarbonyl, cyano; -SO,R™; cyano; -SO:N(R™)R"; -8-R™ or -SOR™: or R! and R? or
R? and R® denote, together with the carbon atoms to which they are attached, an aromatic or aliphatic carbocyclic group having 5 to 10 ring atoms or an aromatic or aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur;
R® is —CH,-O-C(O)-N(R™)R"?, —-CH,-X-C(0)-R"™, C;-Cjalkyl or hydroxyCi-C,alkyl;
R’, R® and R® independently are C;-Cialkyl;
R™ and R"' independently are hydrogen, C,-Caalkyl; C.-Cialkenyl; Cs-Cicycloalkyl; Cs-
C;cycloalkylC4-Caalkyl; Ci-CaalkoxyCy-Cialkyl; C,-Caalkylcarboxy; hydroxyC;-CsalkoxyCi-
Csalkyl; hydroxy; hydroxyCy-Cialkyl; phenylCy-Cqalkyl which is optionally substituted by hydroxy, C,-C,alkoxy, carboxy, C,-C4alkoxycarbonylC-Calkyl, C-C,alkoxycarbonyi, cyano; or R"® and R*"' form together an aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur;
R' and R" independently are hydrogen, Cs-Caalkyl, C-Csalkenyl, Cs-Crcycloalkyl, Cs-
C,cycloalkylC;-Csalkyl, C-CsalkoxyCs-Caalkyl, hydroxyC,-CsalkoxyC,-Caalkyl, hydroxyCi-
C.alkyl, dihydroxyC-Caalkyl, C+-C.alkoxycarbonylC-Csalkyl, C,-C,alkoxycarbonyl, cyano, -
SOR", -SON(RVR", -S-R", -SOR", -C,-Cy-alkylene-SO;R", -C,-C,-alkylene-SOR™, -
C,-C4-alkylene-NH-SO.R™, -C,-C,-alkylene-CON(R")R", -CON(R')R", -C;-C,-alkylene-
C(O)OR™ fluoroalkyl, or R'? and R™ form a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms;
R'is NH, C,-Csalkyl-NH-, C-C,alkenyl-NH-, C;-Cicycloalkyl-NH-, C+-CreycloalkylCs-Caalkyl-
NH-, C,-CaalkoxyCi-Csalkyl-NH-, hydroxyC-CsalkoxyC;-Calkyl-NH-, hydroxyC,-Csalkyl-
NH-, dihydroxyC,-Caalkyl-NH-, C,-C.alkoxycarbonylCy-Caalkyl-NH-, C,-C.alkoxycarbonyl-
NH-, -NH-C,-C,-alkylene-CN, -NH-SO;R'®, -NH-SON(R"R", -NH-C,-C-alkylene-S-R'?, -NH-
SOR, -NH-C,-Cq-alkylene-SO,R"®, -NH-C,-C-alkylene-SOR™, -NH-C4-Cy-alkylene-NH-
SO,R', -NH-C,-C-alkylene-CON(R™)R"", -NH-CON(R™)R"", -NH-C,-C-alkylene-
C(O)OR", -NH-fluoroalkyl, or a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms;
Xis O or CHa; with the proviso that when R' is either halogen, methyl, ethyl, methoxy, trifluoromethyl or hydrogen and R?, R®, R* are either hydrogen, methyl or methoxy and R® is hydrogen or methyl, R'? is neither hydrogen, CCaalkyl, C>-C,alkenyl, hydroxyC,-Csalkyl, -C4-Cs- alkylene-SO,R", nor -C,-C-alkylene-SOR'; in free base or acid addition salt form.
Compounds of the invention exist in free or salt, e.g. acid addition salt form. The invention is to be understood as including the compounds of formula | in free as well as in acid addition salt form, e.g. as trifluoroacetate or hydrochloride salt. Suitable pharmaceutically acceptable acid addition salts for pharmaceutical use in accordance with the invention include in particular the hydrochloride salt.
In formula | the following residues are preferred independently, collectively or in any combination or sub-combination: (a) R' is hydrogen, chloro, methyl, methoxy, -CH,C(O)OCHs, -CH,CH,C(O)OCHj, -
C(O)N(CHsa),, —C(O)OCH,, cyano, -SOz-1-pyrrolidinyl, -SO,CHs, -SO,NHCH;, -SO,N(CHs)2, -
SO,N(CH3)CH,COOH, -S-CHs, -SOCH; or R' forms with R* a -NH-CH,-CH,-CHz- or-CH=CH-
CH=CH- ring. R' is more preferably -SO,;NHCHj;
(b) R? is hydrogen, chloro, methyl, tri-fluoromethyl, or forms with R' a -NH-CHx-CHz-CHz-, -
CH=CH-CH=CH:- ring or with R® a -CH=CH-CH=CH- ring. More preferably R? is hydrogen; (c) R® is hydrogen, fluoro, methyl, or forms with R? a -CH=CH-CH=CH- ring. More preferably R® is hydrogen and chloro; - (d) R* is hydrogen, chloro, more preferably hydrogen; (e) R® is hydrogen, chloro, more preferably hydrogen; (f) R® is methyl, hydroxymethyl, ~CH,-0-C(O)-N(R™)R™ and ~CH,-X-C(O)-R"; (9) R” and R® are methyl; (h) R%is ethyl or propyl, more preferably ethyl; (i) R' is 1-pyrrolidinyl, -CH,.COOH, methyl, hydrogen, more preferably methyl; (k) R"" is methyl, hydrogen, more preferably hydrogen;
Mm R'2 is methyl, ethyl, propyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3 dihydroxypropyl, 1- (hydroxymethy!)-2-hydroxyethyl, cyano, —CH,CH,-SO,CHs, -CH;CH;-S-CHs, —CH,CHxNH-
S0,CHs, ~CH,C(O)OCH3,—~CH,CONH, 2,2,2-trifluoro-ethyl, or forms with R"*a -CH;-CH;-
CHOH-CH,-CH.- ring. More preferably R*? is ethyl and 2-hydroxyethyl; (m) R" is hydrogen or forms with R"? a —CH,-CH,-CHOH-CH,-CHg- ring; (n) RY is —NH-CHs, ~NH-CH,CHs, ~NH-CH,CH;CHs, 2-hydroxyethyl-NH-, 3-hydroxypropyl-NH-, 2,3 dihydroxypropyl-NH-, 1-(hydroxymethyl)-2-hydroxyethyl-NH-, -NH-CH,CN, -NH-CH,CH>
S0,CH;, -NH-CH,CH2-S-CHj, -NH-CH,CH-NH-SO,CHs, —NH-CH,C(O)OCHj3, —NH- : OH OH OH
CH,CONHy, 2,2,2-NH-trifluoro-ethyl, / and / , more preferably / ,
OH i» / and 2-hydroxyethyl-NH-; (0) Xis O.
The present invention also provides a process for the production of a compound of formula | or an acid addition salt thereof, comprising
(i) for the production of a compound of formula | wherein R® Is -CH,-O-C(OMN(R')R* and R” is hydrogen, the step of reacting a compound of formula II
R® . ; RK R
O R
9
R>No NY OR
RE TN R (ny
OH wherein R', R?, R®, R%, R®, R", R®, and R® are as defined above; with a compound of formuta lil (Ili) 0=C=N_ wherein R'? is as defined above; or (ii) alternatively to (i) for the production of a compound of formula | wherein R® is -CH;-O-C(O)-
N(R™)R' and R™ is hydrogen, the step of reacting a compound of formula IV
R?
Rr! rR? 0 FR 9
R ~0 N RY rR
R® NN (6) 0
Y ™
Oo wherein R', R?, R?, R*, R®, R’, R®, and R® are as defined above; with a compound of formula V v)
NH, /
R™ wherein R'? is as defined above; or (iii) for the production of a compound of formula | wherein R® = —CH,-X-C(0)-R* and X = CH, the step of reacting a compound of formula VI
R?
R! rR? oO RO 9
Ro N R* 0 A R°
R N
OH (Vi) 0) wherein R', R?, R®, R*, R®, R’, R®, and R’ are as defined above; with a compound of formula VII
H—R™ (Vit) wherein R' is as defined above; or (iv) for the production of a compound of formula | wherein R® = —-CHz-X-C(O)-R" and X = 0, reacting a compound of formula Vil
R?
R? R®
Oo RO 9
RN YY R*
R® CON R 0) 0) hig (Vit)
Oo wherein R', R?, R®, RY, R%, R", R®, and R® are as defined above; with a compound of formula Vii; or :
(v) for the production of a compound of formula | wherein R® is C;-C4alkyl or hydroxyCi-Cjalkyl, the step of reacting a compound of formula IX
RA
: RK R’
O R O
4
N R (1X)
LY K
R N R wherein R', RZ R%, R*, R®, R” and R® are as defined above and R® is C;-C.alkyl or hydroxyCi-
Cialkyl; with a compound of formula X
Y—R® (X) wherein R® is as defined above and Y is a leaving group, e.g. halogen, e.g. Br; and recovering the so obtained compound of formula | in free base or in acid addition salt form.
Process (i) may be performed according to conventional procedures, e.g. as described in example 1. This process (i) is preferred in cases where the particular isocyanate is commercially available or easily prepared. Processes (ii), (iii), (iv) and (v) may be performed according to conventional procedures, e.g. as described in the relevant examples.
Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures.
Acid addition salts may be produced from the free bases in known manner, and vice-versa.
The starting compounds of formulae Ii, Ill and V are known or may be produced in analogous manner to known procedures, e.g. as described in example 1. Compounds of formula IV may be produced by reacting a compound of formula If with, e.g. phenyl chloroformate.
The starting compounds of formulae VI, VII, VIII, IX and X are known or may be produced in analogous manner to known procedures, e.g. as described in relevant examples.
The compounds of the invention and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals. in particular the agents of the invention exhibit cannabinoid (CB) receptor binding activity. More particularly the agents of the invention are active at the human CB1 and CB2 receptor.
Cannabinoid receptor interaction of the agents of the invention may be demonstrated by their ability to displace e.g. [PH)CP55940 from human cannabinoid receptors expressed in, e.g.
HEK293 or CHOK1 membranes, e.g. as demonstrated in accordance with the following test methods.
Test I: CB1 receptor binding assay
The assay mixture comprises 75 pL of membrane suspension [membranes from HEK293 cells transfected with human CB1 receptors from Receptor Biology, Beltsville, MD.; 133 pg/mL in assay buffer (50 mM Tris-HCI, 2.5 mM EDTA, 5 mM MgCl, 5 mg/mL BSA, pH7.4), approx, pgiwell)], 25 pl. WGA-YS beads [Yttrium silicate beads coated with wheat germ agglutinin,
Amersham (40 mg/mL, 1 mg/well)], 50 pL test compound in 4 % DMSO and 50 pL radioligand {*HICP55940 (180 Ci/mmol), New England Nuclear; final concentration 0.125 nM, in assay buffer}. All components are mixed, shaken at room temperature for 2 hours, then counted on a
Topcount. Non-saturable binding is measured in the presence of 10 uM (R)-(+){2,3-dihydro-5- methyl-3-{(4-morpholinyl)methyl]pyrrolo[1,2,3-de}-1 ,4-benzoxazin-6-yl](1- naphthalenyl)methanone (WIN55,212-2, Tocris).
K, values for the CB1 receptor binding assay are in the range of 1 nM to 100 pM, preferentially from 4 nM to 1 pM for the agents of the invention. The ICs values are calculated in ORIGIN using a logistic fit. K; values are calculated from the ICs values using the Cheng-Prussoff equation (K; = ICs/(1+ ([LVKa)) where [L] is the ligand concentration.
Test ll: CB2 receptor binding assay
The assay mixture comprises 75 pL of membrane suspension [membranes from CHOK1 cells transfected with human CB2 receptors from Receptor Biology, Beltsville, MD.; 133 Hg/mL in assay buffer (50 mM Tris-HCI, 2.5 mM EDTA, 5 mM MgCl, 5 mg/mL BSA, pH7.4), approx, 10 pg/well)], 25 pL. WGA-YS beads [Yttrium silicate beads coated with wheat germ agglutinin,
Amersham (40 mg/mL, 1 mg/well)], 50 pL test compound in 4 % DMSO and 50 pL radioligand
{’HICP55940 (180 Ci/mmol), New England Nuclear; final concentration 0.125 nM, in assay buffer}. All components are mixed, shaken at room temperature for 2 hours, then counted on a
Topcount. Non-saturable binding is measured in the presence of 10 uM (R)-{+}-[2,3-dihydro-5- methyl-3-{(4-morpholinyl)methyi]pyrrolo[1 ,2,3-de}-1,4-benzoxazin-6-yi)(1- naphthalenyl)methanone (WIN55,212-2, Tocris).
K, values for the CB2 receptor binding assay are also in the range of 1 nM to 100 pM, preferentially from 4 nM to 1 pM for the agents of the invention. The ICs values are calculated in ORIGIN using a logistic fit. K, values are calculated from the ICs values using the Cheng-
Prussoff equation (K; = ICsy/(1+ ([LVKq)) where [L] is the ligand concentration.
The agents of the invention are thus useful in the treatment or prevention of disease conditions in which cannabinoid receptor activation plays a role or is implicated, e.g. in chronic pain, especially inflammatory, e.g. chronic inflammatory pain, inflammatory diseases for example inflammatory airways disease, e.g. Chronic Obstructive Pulmonary Disease (COPD), or in asthma, rhinitis, inflammatory bowel disease, cystitis, e.g. interstitial cystistis, pancreatitis, uveitis, inflammatory skin disorders and rheumatoid arthritis.
Activity specifically as analgesic agents may be confirmed in accordance with standard test methods, e.g. as described in the following test.
Test Ili: Neuropathic pain model
Hyperalgesia is examined in the model of neuropathic pain induced by partial ligation of the sciatic nerve as described by Seltzer et al. (1990). Briefly, Wistar rats (120-140 g) are anaesthetised, the left sciatic nerve exposed at mid-thigh level through a small incision and 1/3 to 1/2 of the nerve thickness tightly ligated within a 7.0 silk suture. The wound is closed with a single muscle suture and skin clips and dusted with Aureomycin antibiotic powder. The animals are allowed to recover and used 12-15 days following surgery.
Mechanical hyperalgesia is assessed by measuring paw withdrawal thresholds to an increasing pressure stimulus placed onto the dorsal surface of the paw using an analgesymeter (Ugo-
Basile, Milan) with a cut-off of 250 g. Withdrawal thresholds are measured on both the ipsilateral (ligated) and contralateral (unligated) paw prior to (predose) and then up to 6 h following drug or vehicle administration. Data are expressed as withdrawal threshold (g) and percentage reversal of hyperalgesia calculated according to the following formula:
ipsilateral threshold postdose ipsilateral threshold predose_ X 100 % reversal = contralateral threshold predose — ipsilateral threshold predose
Potency is expressed as Dg value, i.e. the dose of compound necessary to produce 50 % reversal of hyperalgesia.
Ds, values are in the range of 0.1 mg/kg to 100 mg/kg for the agents of the invention.
Activity specifically as CB1 agonists may be confirmed in accordance with standard test methods, e.g. as described in the following test.
Test IV: CB1 functional assay
G-protein activation is used as a functional measure of receptor-ligand association for G-protein coupled receptors. The basic mechanism behind G-protein activation is the exchange of bound guanosine 5'-diphosphate (GDP) for guanosine 5'-triphosphate (GTP). Using a radioactive, non- hydrolyzable form of GTP, such as guanosine 5*-O-(3-[S}thiophosphate (®*SIGTPyS), G- protein activation is assessed by measuring the accumulation of membrane-bound radioactivity in response to receptor activation.
The assay buffer comprises 25 mM HEPES (2.98 g/0.5 L), 10 mM anhydrous MgCl, (476 mg/0.5 L), 100 mM NaCl (2.92 g/0.5 L) and 0.1% Bovine Serum Albumin (0.5 g/0.5L). Fora single 96 well plate experiment, all of the following reagents are prepared in assay buffer: 10 x
GDP (Sodium salt; Sigma, catalogue no. G-7127; 0.004 g/ 10 mL = 10 mM, dilute 1:20 for 500 pM); 10 x GTPyS (Tetralithium salt; Sigma, catalogue no. G-8634; 1 mM stock, dilute 1:10 for 100 pM); 10 x (**S}]-GTPyS (NEN Life Science, catalogue no. NEGO30H, 250 pCi/ 20 pL; 10 uM stock, dilute1:20,000 for 0.5 nM); hCB1 receptor membrane (HEK293 cells; Receptor Biology inc, catalogue no. RBhCB1 382200), 10 pg per well (stock 9.23 mg/mL, receptor concentration (Bmax): 1.21 pmol/mg protein) = 103 pL of cannabinoid supplied membrane in 9497 uL of buffer (the membrane vial is thawed, rapidly diluted with assay buffer and kept on ice); 5 x WGA PVT
Scintillation Proximity Assay (SPA) Beads (Amersham International, catalogue no. RPNQO001; mg/mL) and 10 x Test compound/ DMSO control.
The following are pipetted into Packard PicoPlate — 96 plates (volumes/welis) to give a total assay volume of 250 pL: 25 pL of 10 x (500 pM) GDP or Buffer (for total binding); 25 pL of 10 x
Test compound/ DMSO control; 25 pL of 10 x GTPyS (for non specific binding) or Buffer; 25 pL of 10 x [**S}-GTPYS; 100 pL of Human Cannabinoid receptor (10 pg per well); 50 pL of (20 mg/mL) WGA PVT SPA beads (1 mg per well). The plate is sealed with a topseal A cover and vortexed for 2 minutes. The plate is incubated at room temperature for 60 min., centrifuged (Beckman 6JB) at 800g for 5 minutes and counted on a Topcount for 3 minutes.
Non-specific binding is determined using 10 pM GTPYS, and this is subtracted from all values.
Basal binding is assayed in the absence of agonist and in the presence of GDP. The stimulation by agonist is defined as a percentage increase above basal levels, i.e., {cpm (agonist) — cpm (no agonist)/cpm (no agonist)} x 100
Data are reported as mean + S.E.M. of one to six experiments performed in triplicate. Non- linear regression analysis of concentration-response data is performed using Origin version 5, (logistics algorithm; Microcal Software Inc. MA, USA) to calculate percentage maximal effect (Emax, %) and ECso (nM) values. Emax is the maximal activity of the test compound compared to that of WIN55,212-2 on the same plate.
ECs, values are in the range of 1 nM to 50 pM, preferentially from 2 nM to 3 pM for the agents of the invention. Eqax Values are in the range of 52% to 180%, preferentially from 80% to 180% for the agents of the invention.
The agents of the invention are thus in particular useful as cannabinoid receptor agonists, e.g. for the treatment of pain of various genesis or aetiology and as anti-inflammatory and/or anti-oedemic agents for the treatment of inflammatory reactions, diseases or conditions, as well as for the treatment of allergic responses. Having regard to their analgesic/anti-inflammatory profile they are useful for the treatment of inflammatory pain, for the treatment of hyperalgesia and, in particular, for the treatment of severe chronic pain. They are, for example, useful for the treatment of pain, inflammation and/or oedema consequential to trauma, e.g. associated with bums, sprains, fracture or the like, subsequent to surgical intervention, e.g. as post-operative analgesics, as well as for the treatment of inflammatory pain of diverse genesis, e.g. for the treatment of bone and joint pain (osteoarthritis), rheumatoid arthritis, rheumatic disease, teno-synovitis, gout, cancer pain, myofascial pain (muscular injury, fibromyalgia), lower back pain, chronic neuropathic pain, e.g. diabetic neuropathy, phantom limb pain and perioperative pain (general surgery, gynecologic surgery). They are further suitable as analgesics for the treatment of pain associated with, e.g., angina, menstruation or cancer. As anti-inflammatory/anti-oedema agents, they are further useful, e.g., for the treatment of inflammatory skin disorders, for example psoriasis and eczema.
The agent of the invention are also useful for the treatment of chronic psychiatric diseases, such as depressions, depression and bipolar disorders, e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired. In addition, the compound is indicated in ADHD (attention deficit hyperactivity disorders) and other attention disorders, e.g. autism, anxiety states, generalized anxiety and agoraphobia, as well as those behavioural states characterized by social withdrawal e.g. negative symptoms, and for the treatment and prevention of neurodegenerative disease, e.g.
Alzheimer, Parkinson.
The agents of the invention are also useful as smooth muscle relaxants, e.g. for the treatment of spasm of the gastro-intestinal tract or uterus, e.g. in the therapy of Crohn's disease, ulcerative colitis or pancreatitis and for the treatment of muscle spasticity and tremor in e.g. multiple sclerosis.
Furthermore, the agents of the invention are also useful in the treatment of ocular disorders selected from the group consisting of glaucoma, normal tension glaucoma and neurodegenerative diseases conditions of the retina and the optic nerve, especially in patients presenting risk factors for glaucoma, such as but not exclusively high intraocular pressure, family history of glaucoma, glaucoma in the contralateral eye and high myopia.
Efficacy in said ocular disorders can be established in the following animal models (for a comprehensive discussion of the models see Goldblum and Mittag, Vision Research 42 (2002) 471-478): (1) experimental glaucoma induced by increased intraocular pressure obtained - by laser photocoagulation of the trabecular meshwork in rats (Ueda et al., Japan. J.
Ophthalmol. 1998; 42:337-344), rabbits and monkeys (March et al., Lasers Surg. Med. 1984; 4:329-335, Pederson and Gaasterland, Arch. Ophthalmol. 1984; 102:1689-1692) - by cautery of two or three episcleral/limbal veins in rats (as described in Shareef et al,
Exp. Eye Res. 1995; 61: 379-382, Mittag et al., Invest. Ophthalmol. Vis. Sci. 2000; 41:3451-3459) - by injection of hypertonic saline into limbal aqueous humor collecting veins of rats (as described in Morrison et al., Exp. Eye Res. 1997; 64: 85-96)
- by intraocular injection of alpha-chymotrypsin in rabbits (as described in Femandez-
Durango et al., Exp. Eye Res. 1991; 53: 591-596) - by intraocular injection of S-antigen in rats (Mermoud et al., Graefes Arch. Clin. Exp.
Ophthalmol. 1994; 232:553-560) (2) experimental glaucoma induced by optic nerve (ON) injury obtained - by ON crush in mice (Levkovitch-Verbin et al., Invest. Ophthalmol. Vis. Sci. 2000; 41: 4169-4174) and rats (Yoles and Schwartz, Exp. Neurol. 1998; 153:1-7) - by ON transection in rats (as described in Martin et al., Invest. Ophthalmol. Vis. Sci. 2002; 43: 2236-2243, Solomon et al. J. Neurosci. Methods 1996; 70:21-25) - by experimental transient (acute) retinal ischemia in rats after ophthalmic vessel ligature (as described in Lafuente et al., Invest. Ophthalmol. Vis. Sci. 2001; 42:2074- 2084) or cannulation of the anterior chamber (Buchi et al., Ophthalmologica 1991; 203:138-147) - by intraocular endothelin-1 injection in rats (Stokely at al., Invest. Ophthalmol. Vis. Sci. 2002; 43: 3223-3230) or rabbits (Takei et al., Graefes Arch. Clin. Exp. Ophthalmol 1993; 231:476-481) (3) experimental glaucoma induced by excitotoxicity in rats (intraocular injection of excitatory amino acids or their analogues as described in Vorwerk et al., Invest. Ophthalmol. Vis. Sci. 1996; 37:1618-1624) (4) spontaneous development of a secondary form (pigment dispersion) of glaucoma in mice (DBA/2J, DBA/2Nnia, and AKXD28/Ty mice as described in Anderson et al., BMC Genetics 2001; 2:1, Chang et al., Nature Genetics 1999; 21: 405-409, John et al., Invest. Ophthalmol.
Vis. Sci. 1998; 39: 951-962, Sheldon et al., Lab. Animal Sci. 1995; 15:508-518)
In the present description the terms “treatment” or “treat” refer to both prophylactic or preventative treatment as well as curative or disease modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
For the above indications the appropriate dosage of the agents of the invention will, of course, vary depending upon, for example, the host, the mode of administration and the nature and severity of the condition being treated as well as the relative potency of the particular agent of the invention employed. For example, the amount of active agent required may be determined on the basis of known in vitro and in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect. In general, satisfactory results in animals are indicated to be obtained at daily dosages of from about 0.01 to about 20.0 mg/kg p.o. in humans, an indicated daily dosage is in the range of from about 0.7 to about 1400 mg/day p.o., e.g. from about 50 to 200 mg, conveniently administered once or in divided doses up to 4 x per day or in sustained release form. Oral dosage forms accordingly suitably comprise from about 0.2 to about 700 mg of an agent of the invention admixed with an appropriate pharmaceutically acceptable diluent or carrier.
The agents of the invention may alternatively be administered e.g. topically in the form of a cream, gel or the like for example for the treatment of conditions of the skin as hereinbefore described or by inhalation, e.g. in dry powder form, for example for the treatment of asthma.
Examples for compositions comprising an agent of the invention include, e.g. a solid dispersion, an aqueous solution, e.g. containing a solubilising agent, a microemulsion and a suspension of, e.g. a hydrochloride salt of a compound of formula | in the range of from-0.1 to 1 %, e.g. 0.5 %.
The composition may be buffered to a pH in the range of, e.g. from 3.5 to 9.5,eg.topH4.5 bya suitable buffer. :
The agents of the invention are also useful as research chemicals.
The agents of the invention can be administered in vivo either alone or in combination with other pharmaceutical agents effective in the treatment of diseases and conditions in which CB1 or CB2 receptor activation plays a role or is implicated including cyclooxygenase-2 (COX-2) inhibitors, such as specific COX-2 inhibitors (e.g. celecoxib and rofecoxib) and nonsteroidal anti- inflammatory drugs (NSAIDs) (e.g. acetylsalicylic acid, propionic acid derivatives), vanilloid receptor antagonists, tricyclic antidepressants (e.g. Anafranil®, Asendin®, Aventyi®, Elavil®,
Endep®, Norfranii®, Norpramin®, Pamelor®, Sinequan®, Surmontil®, Tipramine®, Tofranil®,
Vivactil®, Tofranil-PM®), anticonvulsants (e.g. gabapentin), and GABAg agonists (e.g. L- baclofen).
The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e. a single galenical composition comprising at least two combination partners, according to the invention can be prepared in a manner known - per se and are thus suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application.
Novel pharmaceutical compositions contain, for example, from about 0.1 % to about 99.9 %, preferably from about 20 % to about 60 %, of the active ingredients. Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as sugar-coated tablets, tablets, capsules or suppositories, and furthermore ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar- coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.
In particular, a therapeutically effective amount of each of the combination partners may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination. For example, the method of delay of progression or treatment of a proliferative disease according to the invention may comprise (i) administration of the combination partner (a) in free or pharmaceutically acceptable salt form and (ii) administration of a combination partner (b) in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily dosages corresponding to the amounts described herein. The individual combination partners can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. Furthermore, the term administering also encompasses the use of a pro-drug of a combination partner that converts in vivo to the combination partner as such. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.
The effective dosage of each of the combination partners employed may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, the severity of the condition being treated. Thus, the dosage regimen is - selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients’ availability to target sites. In general, satisfactory results in animals are indicated to be obtained at daily dosages of from about 0.01 to about 20.0 mg/kg p.o. In humans, an indicated daily dosage is in the range of from about 0.7 to about 1400 mg/day p.o., e.g. from about 50 to 200 mg, conveniently administered once or in divided doses up to 4 x per day or in sustained release form. Oral dosage forms accordingly suitably comprise from about 0.2 to about 700 mg.
In accordance with the foregoing, the present invention also provides: (1) An agent of the invention for use as a cannabinoid receptor agonist, for example for use in any of the particular indications hereinbefore set forth; (2) A pharmaceutical composition comprising an agent of the invention as active ingredient together with a pharmaceutically acceptable diluent or carrier therefor. Such a composition may be manufactured in a conventional manner. (2') A pharmaceutical composition for the treatment or prevention of a disease or condition in which cannabinoid receptor activation plays a role or is implicated comprising an agent of the invention and a carrier. (3) A method for the treatment of any particular indication hereinbefore set forth in a subject in need thereof which comprises administering an effective amount of an agent of the invention;
(3) A method for treating or preventing a disease or condition in which cannabinoid receptor activation plays a role or is implicated comprising administering to a mammal in need thereof a therapeutically effective amount of an agent of the invention. (4) The use of an agent of the invention for the manufacture of a medicament for the treatment or prevention of a disease or condition in which cannabinoid receptor activation plays a role or is implicated; (5) A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of an agent of the invention and a second drug substance, said second drug substance being for example for use in any of the particular indications hereinbefore set forth. (6) A combination comprising a therapeutically effective amount of an agent of the invention and a second drug substance, said second drug substance being for example for use in any of the particular indications hereinbefore set forth.
The preferred compound of formula | for use in accordance with the invention is that of Example 2. . This compound is a potent CB agonist (ECs in the CB1 functional assay of test IV = 0.132 + 0.019 pM; Emax = 117 £5 %), in particular CB1 agonist, in vitro (Ki in the CB1 receptor binding assay of test | = 0.034 + 0.003 uM) and CB2 agonist, in vitro (Ki in the CB2 receptor binding assay of test Il = 0.011 + 0.0035 uM). The Ds, value in the neuropathic pain model of test Il for the compound of example 2 is 0.5 mg/kg p.o.
Abbreviations used in the examples:
AcOH = Acetic acid; HCI = Hydrochloric acid; KOH = Potassium hydroxide; MeCN = Acefonitrile;
MgSO, = Magnesium sulfate; Na,SO, = Sodium sulfate; NaHCO, = Sodium hydrogen carbonate;
TFA = Trifluoroacetic acid; THF = Tetrahydrofuran
The following examples illustrate the invention.
Example 1: Preparation of 2-Ethylcarbamoyloxymethyi-5,7-dImethyl-3-(2- methyisulfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid ethyl ester a) Preparation of 3, 5-Dimethyl-benzene-1,2, 4-tricarboxylic acid 4-ethyl ester 1,2-dimethyl ester:
A yellow, viscous reaction mixture of ethyl isodehydracetate (300 g, 1.53 mol) and dimethyl ) acetylenedicarboxylate (434.6 g, 3.06 mol) under an argon atmosphere is heated at ca. 190 °C for 1 h. Vigorous CO evolution is accompanied by formation of a black reaction mixture. The reaction mixture is allowed to cool to ambient temperature under argon overnight. The mixture is dissolved in ethyl acetate/hexane (ca. 700 mL, 1:2) and purified by filtration through silica gel (5 kg), eluting with hexane/ethyl acetate (3:1) to give the title compound as a yellow oil (427 g, 94.9%). b) Preparation of 3, 5-Dimethyl-benzene-1,2,4-tricarboxylic acid 4-ethyl ester 2-methyl ester: A stirred pale yellow solution of 3,5-dimethyl-benzene-1 2 4-tricarboxylic acid 4-ethyl ester 1,2- dimethyl ester (421 g, 1.43 mol) in methanol (10.2 L) is treated at room temperature with 5M
KOH solution (5.74 L) whereupon a light brown solution was formed. The reaction mixture is stirred at room temperature for 35 min, TLC (ethyl acetate: AcOH, 20:1) indicating complete reaction after ca. 15 min. The yellow-brown reaction mixture is treated with ice (3 kg) and extracted with tert-butyl methyl ether (2 x 15 L). The organic phase is additionally extracted with brine (5 L). Concentrated HCI solution (2.5 L) is added to the aqueous phase until a pH of 1 was achieved, maintaining the temperature below 30 °C with addition of ice as necessary. The acidified aqueous layer is extracted with ethyl acetate (2 x 3 L), and the organic phases were backwashed with brine (2 L). The combined organic phases are dried over anhydrous Na;SO,, filtered and the solvent removed under reduced pressure to afford the title compound as a white crystalline solid (377 g, 94%). c) Preparation of 4-tert-Butoxycarbonylamino-2, 6-dimethyl-isophthalic acid 1-ethyl ester 3- methyl ester: A stirred yellow solution of 3,5-dimethyl-benzene-1 ,2,4-tricarboxylic acid 4-ethyl ester 2-methy! ester (374 g, 1.33 mol), diphenylphosphoryl azide (734 g, 576 mL, 2.66 mol) and triethylamine (270 g, 371.4 mL, 2.66 mol) in tert-butanol (4.2 L) is heated at reflux for 1.5 h.
Vigorous N; evolution is accompanied by formation of a clear brown solution. The reaction mixture is cooled to ca. 50 °C and evaporated to dryness in vacuo to afford a dark brown oil (1.4 kg). This is re-dissolved in dichloromethane (3 L) and washed sequentially with saturated
NaHCO; solution (2 x 2 L) and brine (2 L). The combined aqueous layers are back-washed with dichloromethane (1 L). The combined organic layers are dried over anhydrous Na,SOx, filtered and the solvent is removed under reduced pressure to afford a dark brown oil (1.14 kg). The crude product is dissolved in hexane/ethyl acetate (1 L, 1:1) and purified by filtration through silica gel (6 kg), eluting with hexane/ethyl acetate (8:1) to afford the title product as a yellow, waxy solid (441.5 9, 94.2%). d) Preparation of 4-Amino-2, 6-dimethyl-isophthalic acid 1-ethyl ester 3-methyl ester: A stirred clear yellow solution of 4-tert-butoxycarbonylamino-2,6-dimethyl-isophthalic acid 1-ethyl ester 3- methyl ester (435 g, 1.24 mol) in dichloromethane (825 mL) under nitrogen is treated with TFA (825 mL) at room temperature, whereupon CO, evolution was observed. After stirring at ambient temperature for ca. 1.5 h, the reaction mixture is evaporated to dryness in vacuo. The residue is re-dissolved in ethyl acetate (2 L) and sequentially washed with water (2 L), 50%
NaHCO; solution (2 L), saturated NaHCO; solution (2 L) and brine (2 L). The combined aqueous phases are back-washed with ethyl acetate (1 L). The combined organic layers are dried over anhydrous Na,SOs, filtered and the solvent is removed under reduced pressure. The resulting thick pulp is treated with hexane (2 L), cooled to 0 °C with stirring and stirred vigorously for 1 h. The suspension is filtered, washed well with cold hexane and dried at 40 °C to constant weight to afford the title product as a white crystalline solid (231.5 g, 74.4%). e) Preparation of 4-Amino-2, 6-dimethyl-isophthalic acid 1-ethyl ester: A stirred white suspension of 4-amino-2,6-dimethyl-isophthalic acid 1-ethyl ester 3-methyl ester (225 g, 0.89 mol) in methanol (5.9 L) under a nitrogen atmosphere is treated at room temperature with 5M KOH solution (3.58 L). The reaction mixture is heated to ca. 80 °C, whereupon a clear, colourless solution is finally formed. After heating for 1 h, the reaction mixture is cooled to ca. 40 °C.
Methanol is removed under reduced pressure and the remaining aqueous phase is extracted with tert-butyl methyl ether (2 x 3 L). The organic phase is back-extracted with water (0.5 L).
Concentrated HCI solution (2.5 L) is added to the combined aqueous phases until a pH of 1 is achieved, maintaining the temperature below 30 °C with addition of ice as necessary. The acidified aqueous layer is extracted with ethyl acetate (2 x 3 L), and the organic phases are backwashed with brine (2 L). The combined organic phases are dried over anhydrous Na;SOj,, filtered and the solvent concentrated to a volume of ca. 1 L. The yellow ethyl acetate solution is diluted with hexane (2 L) and stored at 0 °C for 1 h. The resulting white suspension is filtered, thoroughly washed with hexane/ethyl acetate (8:2) and dried at 40 °C to constant weight to afford the title product as a white crystalline solid (194 g, 84.9%). A further 17.8 g (7.8%) can be recovered from the mother liquor. 7) Preparation of 4-(Benzyloxyacetyl)amino-2, 6-dimethyl-isophthalic acid 1-ethyl ester: To a stirred solution of 4-amino-2,6-dimethyl-isophthalic acid 1-ethyl ester (25 g, 0.1054 mol) in anhydrous dichloromethane (250 mL) at ice-bath temperature is added diisopropylethylamine (18 mL, 0.421 mot) in one lot followed by benzyloxyacetyl chloride (Aldrich, 18 mL, 0.1159 mol),
dropwise. The reaction mixture is allowed to warm to room temperature overnight. TLC/LCMS analysis indicated that the reaction is complete. The reaction mixture is evaporated to dryness and the residue is partitioned between ethyl acetate and 2 M HCL. The organic phase is separated, dried over anhydrous Na,SO, and evaporated to give a yellow solid.
Recrystallization from cyclohexane/ ethyl acetate provides the title compound as a yellow crystalline solid (38.5 g, 0.100 mol, 95%). : g) Preparation of N-Methyl-2-nitro-benzenesulfonamide: To a stirred suspension of 2- nitrobenzenesulfonyl chloride (18.24 g, 0.082 mol) in methanol (35 mL) is added methylamine (2.0 Min THF, 90 mt, 0.18 mol), dropwise, via addition funnel. The reaction mixture is allowed to attain room temperature and is then left overnight. TLC (eluent cyclohexane/ethyl acetate 1/1) indicated that some starting material remained. Additional methylamine (2.0 Min THF, 30 mL) is added and the mixture was stirred for 1 h. TLC then indicated that the reaction is complete. The reaction mixture is evaporated in vacuo and the residue is partitioned between water and ethyl acetate. The organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with saturated aqueous NaHCO; solution, brine and then dried over anhydrous MgSO.. Evaporation in vacuo provides the title compound as pale yellow crystals (16.91 g, 0.078 mol, 95%). h) Preparation of 2-Amino-N-methyl-benzenesulfonamide: A solution of N-Methyl-2-nitro- benzenesulfonamide ( 17 g, 0.078 mol) in anhydrous THF (200 mL) is degassed under house vacuum. Palladium on activated charcoal (10% Pd, 3.7 g) is added and the stirred suspension was flushed with hydrogen (balloon). The suspension is stirred under hydrogen overnight. TLC analysis shows that the reaction is complete. The reaction mixture is then filtered through Celite.
The spent catalyst is washed sequentially with ethyl acetate and methanol. Evaporation in vacuo provides the title compound as a viscous, pale brown oil ( 14.6 g, 100%). i) Preparation of 2-Benzyloxymethyl-5, 7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4-oxo-3,4-di- hydro-quinazoline-6-carboxylic acid ethyl ester: To a mechanically-stirred suspension of 4- (Benzyloxyacetyl)amino-2,6-dimethyl-isophthalic acid 1-ethyl ester (27 g, 0.07 mol), 2-amino-N- methyl-benzenesulfonamide (13 g, 0.07 mol) and anhydrous toluene (500 mL) in a three- necked round bottom flask is added phosphorus trichloride (51 mL, 0.56 mol) via an addition funnel. The reaction mixture is stirred at room temperature for 5 minutes and then heated to reflux. After 45 minutes LCMS analysis indicates that the reaction is complete. The suspension is cooled to room temperature and the solution phase is decanted from the solid material. The solution and solid material are worked-up separately. The toluene solution is portioned between ethyl acetate and saturated aqueous NaHCO; solution with vigorous stirring to give a clear biphasic solution. The organic and aqueous phases are separated and the aqueous phase is extracted (x 2) with ethyl acetate. The organic phases are combined, dried over anhydrous
Na,SO,, and evaporated in vacuo to give an orange oil. Similarly, the solid material is stirred vigorously with ethyl acetate and saturated aqueous NaHCO; solution to give a clear biphasic ) solution. The organic and aqueous phases are separated and the aqueous phase is extracted (x 2) with ethyl acetate. The organic phases are combined, dried over anhydrous Na;SO,, and evaporated in vacuo to give an orange oil. Trituration of the orange oils with diethyl ether provides yellow solids, which are removed by filtration, washed with diethyl ether and air-dried to provide the title compound (20 g, 0.037 mol, 53%). k) Preparation of 2-Hydroxymethyl-5, 7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4-0x0-3,4- dihydro-quinazoline-6-carboxylic acid ethyl ester: A solution of 2-Benzyloxymethyl-5,7-dimethyl- 3-(2-methylsulfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid ethyl ester (15 g, 0.028 mol) in anhydrous THF (270 mL) is degassed under house vacuum. Palladium on activated charcoal (Acros, 10% Pd, 930 mg) is added and the suspension is flushed with hydrogen (balloon). The suspension is stirred under hydrogen overnight. TLC and LCMS analysis indicates that starting material remained. The reaction mixture is filtered through Celite, and the catalyst is washed sequentially with methanol, DCM and methanol. The filtrate is evaporated to give a cream solid. Trituration with diethyl ether provides a white solid which is ‘removed by filtration and dried under high vacuum to provide the title compound (5.42 g, 0.012 mol, 43%). The ethereal filtrate, which contains un-reacted starting material, is evaporated in vacuo and the residue is subjected to a second cycle of hydrogenation (Pd-C, 920 mg): after stirring overnight under hydrogen TLC/LCMS indicated absence of starting material. The reaction mixture is worked-up as above to provide the title compound as a white solid (4.75 g, 0.01 mol, 38%). Total yield: 10.17 g, 0.022 mol, 82%.
I) Preparation of 2-Ethylcarbamoyloxymethyl-5, 7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4- oxo-3,4-dihydro-quinazoline-6-carboxylic acid ethyl ester: To a stirred solution of 2- hydroxymethyl-5,7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-6- carboxylic acid ethyl ester (1.2 g, 2.70 mmol), in anhydrous THF (2 mL) is added ethyl isocyanate (3 mL) in one lot. The resulting suspension is stirred under argon. After 10 minutes, a clear solution results. After 45 minutes TLC/LCMS analysis indicates complete conversion.
The reaction is quenched by the addition of excess methanol and is then evaporated in vacuo to dryness. Purification by flash chromatography on silica (gradient elution with ethyl acetate, 30% to 35% to 65%, in diethyl! ether) provides the title compound as a colourless glass (1.36 g, 2.63 mmol, 98%). Mp 102-115 °C; 'H NMR (400 MHz, CDCl3) 1.12 (3H, t, J=7 Hz), 1.41 3H, t, J=
8 Hz), 2.43 (3H, s), 266 (3H, d, J=5Hz), 2.73 (3H, s), 3.16 (2H, m), 444 (2H,q,J=T7H2), 461 (1H,d, J=14Hz), 473 (1H, d, J = 14 Hz), 4.90 (1 H, bm) overlapping 4.94 (1 H, bm), 7.47 (2H, m), 7.70 (1H, dt, J=1,8 Hz), 7.78 (1 H, dt, J= 2,8 Hz), 8.10 (1 H, d, J =8 Hz), 'H
NMR (400 MHz, CD,0D) 1.11 (3H, t, J= 7 Hz), 1.42 (3 H,t, J=7 Hz), 2.44 (3 H, s), 2.55 (3 H, s), 2.71 (3H,s), 3.08(2H,q,J= 7 Hz), 4.46 (2H, q, J=T7Hz), 458 (1 H, d, J=14 Hz), 4.78 (1H, d, J=14 Hz), 7.48 (1 H, 5), 7.60 (1H,dd, J=1,8Hz), 7.81 (2H, m), 8.12 (1H, dd, J=1, 8 Hz); MS m/z (ES’) 517.1 (M+ 1, 100%); HPLC: retention time = 5.185 min, >96%, column
Phenomex-Kingsorb C18, 3 cm x 4.6 mm ID, solvent system MeCN/H,O (0.1%TFA), gradient to 90% MeCN, 10 min; Detection 254nm. m) Preparation of 2-Eth ylcarbamoyloxymethyl-5, 7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4- oxo-3,4-dihydro-quinazoline-6-carboxylic acid ethyl ester hydrochloride: 2-Ethylcarbamoyl- oxymethyl-5,7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-6- carboxylic acid ethyl ester (504 mg, 0.976 mmol) is dissolved over 10 minutes with vigorous stirring in absolute ethanol (20 mL). To the clear, colourless solution is added concentrated HC! (70 drops), slowly, via pipette. After 5 minutes a dense, white precipitate forms. After stirring for a further 10 minutes, the suspension is evaporated in vacuo and the residue is dried overnight under high vacuum to provide the hydrochloride salt as fine, colourless needles (521 mg, 0.942 mmol, 97%). Mp 126-130 °C; 'H NMR (400 MHz, CD,0D)1.12 (3H, t, J=8 Hz), 1.43 (3H, {, J =7 Hz), 2.48 (3H, s), 2.56 (3H, 5), 2.73 (3H, 5), 3.13 (2H, m), 448 (2H,q,J=7Hz),4.77 (1
H, d, J=15 Hz), 4.90 (1H, d, J=15Hz),7.59 (1 H, 5), 7.68 (1 H,dd, J = 1,8 Hz), 7.88 (2 H, m), 8.15 (1 H, dd, J = 2, 8 Hz); MS m/z (ES) 517.1 (M + 1, 100%).
The following compounds of formula | wherein R® is H, R” and Rare methyl, and R® is ethyl may be prepared by following the procedure of Example 1 but using the appropriate starting materials (Ex = Example; with the following HPLC retention data [min] and ion mass):
Ka -l -0 jon min 3 [Cl [HH _|Cl|H [-CHCHy | 4921[MsJ]64 |] 4 [-CHC(O)OCH; | H _ [-H [H [-H [-CHCH, [496[M+H}* [537
Sc cc Fl cc ll ee 3 cc i Em NH § | S0.CH; __ [H _|-H [-H [-H [-CHCH, [502[M+Hl+ 52 9 [SCH IH |-H |H [-H [-CHCHy [470(M+HI+[64 10 | -CH=CHGH=CH- __|-H__|-H [CH [-CH,CHy [488[M+HI*|65 1 [-H____ [cl 1-H |-H [HH |-CHCHy [458[M+H}+ [4.96
2 [-80.Ch,____[H__[H_[H [-H [.CHCHCH, | 516 M+H[+ [5.5 ccc i BP Gl
I a SA a lS i H+ Sl 51cm, [HAH [-H | CHCHCH, |484MsHI183 6 [Soc [-H | H _[-H [H [-CHCH, | 486[MeHI]85 eA A all A il hl
C(O)OCHs v =F - - -CH.C .
Ec a la a: il
I Gu ci cl Rl Gi I ll
A+H]+
Cl ct a a wl
M+H}+
Acc al cc J
M+H]+ -SO-- -CH,CH3; 575.2
N(CH3)CH.COO (M+H]+
H
CH=CH- [M+H]+ (24 [H___ [CF, |-H [H]-H [-CHCH, |-H___ [-H [-F [H [-H [-CHCH | 442M+Hp [62 * Column Phenomex-Kingsorb C18, 3 cm x 4.6 mm ID, solvent system MeCN/ H20 (0.1%TFA), gradient 10 to 90% MeCN, 10 min; Detection 254nm.
Example 2: Preparation of 2-(2-Hydroxy-ethylcarbamoyloxymethy!)-5,7-dimethyl-3-(2- methylsulfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-8-carboxylic acid ethyl ester:
To a stirred solution of 2-hydroxymethyl-5,7-dimethyl-3-(2-methylsulfamoyi-phenyi}-4-oxo-3,4- dihydro-quinazoline-6-carboxylic acid ethyl ester (800 mg, 1.79 mmol), in anhydrous pyridine (20 mL) under a nitrogen atmosphere is added phenyi chloroformate (0.566 mL, 4.5 mmol) in one lot. A gelatinous, white precipitate is formed. The stirred reaction mixture is heated to 80 °C.
After 45 minutes TLC/LCMS analysis indicates completion of the reaction. The reaction is allowed to cool and evaporated in vacuo to dryness. The residue is partitioned between ethyl acetate and 2 M HCI. The organic phase is separated, dried over anhydrous NazS0,, and evaporated to give an off-white foam which is dried at high vacuum. The foam is dissolved in anhydrous THF (10 mL) and ethanolamine (2 mL, 33 mmol) is added. The reaction mixture is stirred overnight at room temperature under argon. TLC/LCMS analysis indicates completion of the reaction. The reaction mixture is evaporated in vacuo to dryness and the residue is partitioned between dichloromethane and 2 M HCI. The organic phase is separated, dried over anhydrous Na,SO, and evaporated in vacuo to give an orange oil. Purification by flash chromatography on silica (gradient elution with ethyl acetate, 50% to 70% to 90%, in cyclohexane) provides the title compound as colourless crystals after drying at high vacuum (872 mg, 1.64 mmol, 91%). Mp 122-125 °C; 'H NMR (400 MHz, CDCl3) 1.41 3H. t, J =T7 Hz), 2.30 (1 H, bm), 2.43 (3H, 5), 2.67 (3 H, d, J = 5Hz), 2.74 (3H, 8), 3.27 (2 H, m), 3.66 (2 H, bm), 4.45 (2H, q, J=7 Hz), 4.73 (2H, m), 4.97 (1 H, bm), 5.31 (1 H, bm), 745(1H,d,J=8
Hz), 749 (1H,s), 7.71 (1H, t J=8 Hz), 7.79 (1H, m), 8.10 (1H, d,J=8 Hz); MS m/z (ES") 533.2 (M + 1, 100%); HPLC: retention time = 4.313 min, >99%, column Phenomex-Kingsorb
C18, 3 cm x 4.6 mm ID, solvent system MeCN/ H.O (0.1%TFA), gradient 10 to 90% MeCN, 10 min; Detection 254nm.
The following compounds of formula | wherein R® is -CH,-0-C(O)-NH-R™2, R" and R® are methyl, and R’? is ethyl may be prepared by following the procedure of Example 2 but using the appropriate starting materials (Ex = Example; with the following HPLC retention data [min] and ion mass): i El A ll 0 min
Gr ll IO pyrrolidinyl [M+H]+ 27 ].ct___ |H__|-H [H |-H _|-CHCHyS-CH, | 5044(M#] [63 28 | -SO;N(CHaa_I-H _ |-H |H |-H |-CHCHyOH [547 M+H}+|457 -Cl -H -CH,CF 512.5
EA I a SA i A GN I i A ll al id
OH il Gl Gl i
M+H]+ il ll hc Mid
CH, lc al li
M+H]+ casa A a ll Fi
CH,-OH (M+H]+ lu Gl la E--5
SO,CH 36 | -SOzN(CHy), |H _|H [-H |[-H |-CHCHOH), [577[M+H]+]43
A lll AE
SO,CH 38 | -SO-NHCH; _|-H___[-H | -H [-H [-C(CHs),CH,OH | 561 M*H[> [53 el Sonor
NHCH,CH, [M+H]}+ 40 | -SO,-NHCH; -H GH, 547.0 —C. [M+H]+
H OH
41 [-SO,-NHCH; CH, 547.0 —& [M+H]+
H OH
-SO,-NHCH; -H -H CH, 547.0 —C [M+H]+
H OH
Fc a a a a i HP + : CH,C(O)OCH: [M+H]+ 45 | -SO,-NHCH; y 02 547.1 | 4.9 + —C” “OH [M+H]
CH,
FO ll Fa
CH,-OH [M+H}+ 47 | -SO,-NHCH;3 -C(CHy),-CHz- 561.0
OH {M+H]+ -SO,-NHCH, -H -H H, 547.5 on [M+H]+
CH, -SO,-NHCH,- -H -CH,CH,-OH 547 1
CH; [M+H]+ lc a ce H+ ll
M+H]+
NHCH,CH,CHj [M+H}+ -SO,-NHCH -CH(CH,-OH 563.0 52 | -SOZNHCHs HOA [oeRom: | els i ca Hl : M+H}+
OF a I
M+H]+ lc a a il I HE +Hl+
NHCH(CH, [M+H]+
S57 -CH,CH 5572 | 7.4 oli on -H CH, 561.2
CH.CHs ~c-S on [M+H]+
H, -SO;- CH, 561.2
NHCH,CH;, “gr foon [M+H]}+ -SO,-NHCH; OH 573.0 -SO2-NHCH; -H [-H OH 587.0173
-SO,-NH- oH 601.0 - - H H OH 573.1
Bl SO, NH-CH; Nu co : aH} -S02-NH- -H OH 587.5
His 5 1™ -SO,NH- OH - 587.4
CH,CH; —) M+H}+ "| or EEE [M+H]+ 67 | -SO»NH-CH; Nas H OH 573.1 [M+H]+
The following compounds of formula | wherein R® is -CH-O-C(O)-N(R'2)R", R” and R*are methyl, and R® is ethyl may be prepared by following the procedure of Example 2 but using the appropriate starting materials (Ex = Example; with the following HPLC retention data [min] and ion mass):
Ex ) RT* : [min] cll lll IP ll
CH (M+H]+ cl al ll iil 74 +H]+ -SO,-NHCH, HH [HH -CH,-CH;-(R)-CHOH- 559.2 4°
CH, (M+H]}+ ci ll ll Bc
M+H]+ al ll A
CH(CH,OH)- {M+H]+
H | H |-H | -CHx(R)-CHOH-CH. 573.2
NHCH,CH CH, [M+H]+ -S0,-NHCH,4 (HH [HH -CH-CHz(S)-CHOH- 558.0 5%
CH, [M+H]+ il lll 5 An 3
CHOH-CH»- [M+H]+
Column Phenomex-Kingsorb C18, 3 cm x 4.6 mm ID, solvent system MeCN/ H,0 (0.1%TFA), gradient 10 to 80% MeCN, 10 min; Detection 254nm.
Example 77: Preparation of 3-(2-Chlorophenyl)-2-(2-ethylcarbamoylethyl)-5,7-dimethyl-4- oxo-3,4-dihydroquinazoline-6-carboxylic acid ethyl ester a) 4-(3-Ethoxycarbonylpropionylamino)-2, 6-dimethylisophthalic acid 1-ethyl ester: A stirred solution of 4-amino-2,6-dimethylisophthalic acid 1-ethyl ester (0.3 g, 1.26 mmol) and triethylamine (0.355 mL, 2.55 mmol) in dichloromethane (15 mL) at 0 °C is treated with ethyl succinyl chloride (0.199 mL, 1.39 mmol), and the reaction mixture is allowed to warm to room temperature overnight. The reaction mixture is washed with 1M hydrochloric acid, back-washed with brine and dried over anhydrous MgSO,. The solvent is removed under reduced pressure to afford the title compound, which is used without further purification. : b) 3-(2-Chiorophenyl)-2-(2-ethoxycarbonylethyl)-5, 7-dimethyl-4-oxo-3,4-dihydroquinazoline-6- carboxylic acid ethyl ester: A stirred mixture of 4-(3-ethoxycarbonylpropionylamino)-2,6- dimethylisophthalic acid 1-ethyl ester (0.327 g, 0.89 mmol), 2-chloroaniline (0.28 mL, 2.66 mmol) and phosphorus trichloride (0.74 g, 5.4 mmol) in toluene (6 mL) is heated at 130 °C for 3 h. Upon cooling to room temperature, the reaction mixture is poured onto saturated sodium hydrogen carbonate solution and extracted with chloroform. The chloroform extracts are combined, washed with brine and dried over anhydrous MgSO,. The solvent is removed under reduced pressure and the residue is purified by flash chromatography over silica gel (initial eluent: 19:1 cyclohexane:ethyl acetate; final eluent: 7:3 cyclohexane:ethyl acetate) to afford the title compound. b) 2-(2-Carboxyethyl)-3-(2-chlorophenyl)-5, 7-dimethyl-4-oxo-3, 4-dihydroquinazoline-6- carboxylic acid ethyl ester: A solution of 3-(2-chlorophenyl)-2-(2-ethoxycarbonylethyl)-5,7- dimethyl-4-oxo-3,4-dihydroquinazoline-6-carboxylic acid ethyl ester (0.1 g, 0.22 mmol) in absolute ethanol (6 mL) is treated with 2M sodium hydroxide solution (12 drops) and the reaction mixture is stirred at room temperature for 4 days. The solvent is removed under reduced pressure, and the residue is dissolved in water and washed with ethyl acetate. The aqueous layer is acidified to pH2 with concentrated hydrochloric acid and this is extracted with ethyl acetate. The organic phases are combined, dried over anhydrous MgSO, and the solvent is removed under reduced pressure to afford the title compound, which is used without further purification. c) 3-(2-Chlorophenyl)-2-(2-ethylcarbamoylethyl)-5, 7-dimethyl-4-oxo-3,4-dihydroquinazoline-6- carboxylic acid ethyl ester: A mixture of 2-(2-carboxyethyl)-3-(2-chlorophenyl)-5,7-dimethyl-4-
ox0-3,4-dihydroquinazoline-6-carboxylic acid ethyl ester (0.093 g, 0.217 mmol), ethylamine hydrochloride (0.018 g, 0.221 mmol), 4-(dimethylamino)pyridine (0.027 g, 0.221 mmol), triethylamine (0.066 g, 0.65 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.042 g, 0.219 mmo!) in dichloromethane (10 mL) is stirred at room temperature for 3 days. The solvent is removed under reduced pressure and the residue is dissolved in ethyl acetate. The ethyl acetate solution is washed sequentially with 2M hydrochloric acid, saturated sodium hydrogen carbonate solution and brine. After drying over anhydrous MgSO, the solvent is removed under reduced pressure and the residue is purified by preparative high-performance liquid chromatography to afford the title product. 'H NMR (400 MHz, CDCh): §1.13(3H,t, J= 7.2 Hz), 143 (3H, t,J=7.1 Hz), 244 3H, 5), 2.54-2.62 (2 H, m), 2.70-2.78 (2H, m), 2.78 (3
H, s), 3.25-3.32 (2H, m), 445 (2H,q,J=7.3 Hz), 5.98 (1 H, br s), 7.36 (1 H, s), 7.38-7.39 (1
H, m), 7.47-7.49 (2 H, m), 7.61 (1 H, m).
Example 78: Preparation of 2-(2-Hydroxy-ethylcarbamoyloxymethyl)-5,7-dimethyl-3-(2- methylsulfamoylphenyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid propyl ester a) 2-Hydroxymethyl-5, 7-dimethyl-3-(2-methyisulfamoylphenyl)-4-oxo-3, 4-dihydro-quinazoline-6- carboxylic acid: 2-Benzyloxymethyl-5,7-dimethyl-3-(2-methylsulfamoyi-phenyl)-4-oxo-3,4- dihydro-quinazoline-6-carboxylic acid ethyl ester (3 g, 5.6 mmol) is dissolved in 47% hydrobromic acid. The reaction mixture is stirred at 80 °C overnight, then at 90 °C for 5 h, then at 95°C for a further 5 h. The reaction mixture is evaporated in vacuo to give a brown solid, which is suspended in diethyl ether/ dichloromethane and stirred ovemight. Filtration, followed by washing with dichloromethane then ether and drying in vacuo provides the title compound as a sandy brown solid. b) 2-(2-Hydroxy-ethylcarbamoyloxymethyl)-5, 7-dimethyl-3-(2-methyisulfamoylphenyl)-4-oxo-3,4~ dihydro-quinazoline-6-carboxylic acid propyl ester: To a solution of 2-hydroxymethyl-5,7- dimethyl-3-(2-methylsulfamoylphenyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (200 mg, 0.479 mmol) in pyridine (10 mL) is added, in one portion, phenyl chioroformate (0.361 mL, 2.87 mmol) at room temperature. A white precipitate is formed. The reaction mixture is heated to 80 °C for 2 h and is then evaporated and dried at high vacuum. To the residue is added propanol (30 mL) and dichloromethane (1 mL) to give a solution, which is stirred at room temperature overnight. The reaction mixture is evaporated in vacuo to dryness and the residue is partitioned between dichloromethane and 2.0 M hydrochloric acid. The organic phase is dried (Na;SO.) and evaporated in vacuo to give a yellow oil. The oil is dissolved in THF (5 mL), ethanolamine (1 mL) is added and the reaction mixture is stirred overnight at room temperature. The reaction mixture is evaporated in vacuo to dryness and the residue is partitioned between dichloromethane and 2.0 M hydrochloric acid. The organic phase is dried (Na2S0O,) and evaporated in vacuo to give a yellow oil. Automated gradient elution (10-100% ethyl acetate in hexanes) flash chromatography provides the titte compound as a pale yellow foam. 'H NMR (400 MHz, CDCl3): 61.02 (3H, t, J=7 Hz), 1.80 (2H, m), 2.43 (3 H, 5), 2.66 (3 H, d, J=5Hz), 2.74 (3H, s), 3.26 (2 H, br m), 3.66 (2 H, br m), 4.44 (2H, t, J=7 Hz), 4.72 (2H, m), 5.03 (1H, br m), 5.43 (1 H, br m), 7 46 (2 H, m), 7.71 (1H,t,J=8Hz), 779 (1H,t, J=8Hz), 8. 09 (1 H, d, J = 8 Hz).
The following compounds of formula | wherein R?, R®, R* and R® are H, R® is -CH,-O-C(O)}-R" and R” and R® are methyl may be prepared by following the procedure of Example 78 but using the appropriate starting materials (Ex = Example; with the following HPLC retention data [min] and ion mass).
Ex RT" [min]
SOrNHOH,CR
M+H)+
SO,-NHCH,CH NHCH,CH,OH CH,CH.CH 561 8 | SO_NFOR.CH, [WRCRGROR | CRORCOH: |), |°% ce cl ci 7
M+H)+
M+H)+
SO,-NHCH;, OH CH.CH.CH, 573.1 0 o
N
/
SO2-NHCH, OH CH,CH,CH,CH,CH; | 601 : (M+H)+ » /
SO,-NHCH, OH CH,CH,CH,CH,CH; | 601 o (M+H)+
N
/
SO-NHCH, OH CH,CH.CH,CH3 587.3 : (M+H)+
O
/
N
/ 88 SO,-NHCH;, OH 598.5 : on— (My
J
/
SO,NHCH OH | 643 (M)+ 3 CH ON “
Lo
N
/
SO,-NHCH OH 643 (M)+ ’ : on” NT 9 L_o
N
/ 91 SO-NHCH, OH CH,C(O)OC(CH3;); | 645 : (M+H)+ ® /
S0O,-NHCH, OH CH,CO;H 589.1 : (M+H)+ » /
SO,NHCH;, ~ OH 601
XK o— (M+H)+
SO,-NHCH; ~N OH ] CH,CH,CH; 575 6.72
OK tae
SO,-NHCH OH 587.2
FE H on— > (MH ~~ NO
OH | CH:CH:CH 561.3
SO,-NHCH; " C 2CH2CH; oH) yd NN
HCH OH | CH.CH,CH, 561.3 97 | SO-NHCH; PY 2CH; Mis Hy* _N
SO,-NHCH, OH 599.1
Ko
N
/
SO,-NHCH OH 586.7 6.1 "| j PN cH —> a
N 2
Ve
SO,-NHCH; 0 CH,CH,CH, 558.65
PS we rd N ’ 101 | SO-NHCH; 0 584.69
J [oO [8 yd
HPLC conditions: : Phenomenex Luna reverse phase C18 3 micron 30 x 4.9mm; Gradient elution 10% MeCN in water (+0.08% formic acid) to 100% MeCN over 10 min (rate = 3.0 mL/min; detection = 254 nm).
Example 102: 2-Hydroxymethyl-5,7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4-oxo-3,4- dihydroquinazoline-6-carboxylic acld butyl ester a) Preparation of 3,5-Dimethyl-benzene-1,2,4-tricarboxylic acid 4-ethyl ester 1,2-dimethyl ester:
A yellow, viscous reaction mixture of ethyl isodehydracetate (300 g, 1.53 mol) and dimethyl acetylenedicarboxylate (434.6 g, 3.06 mol) under an argon atmosphere is heated at ca. 190 °C for 1 h. Vigorous CO, evolution is accompanied by formation of a black reaction mixture. The reaction mixture is allowed to cool to ambient temperature under argon overnight. The mixture is dissolved in ethyl acetate/hexane (ca. 700 mL, 1:2) and purified by filtration through silica gel (5 kg), eluting with hexane/ethyl acetate (3:1) to give the title compound as a yellow oil. b) Preparation of 3,5-Dimethyl-benzene-1,2,4-tricarboxylic acid 4-ethyl ester 2-methyl ester: A stirred pale yellow solution of 3,5-dimethyl-benzene-1 ,2,4-tricarboxylic acid 4-ethyl ester 1,2- dimethyl ester (421 g, 1.43 mol) in methanol (10.2 L) is treated at room temperature with 5M
KOH solution (5.74 L) whereupon a light brown solution was formed. The reaction mixture is
Claims (17)
1. A compound of formula R2 R! rR} o R 0
RY. SJ I =® A (1) wherein R' R?, R®, R* and R® independently are hydrogen; halogen; C1-Csalkyl; Cz-Cialkenyl; Cs Cicycloalkyl; C3-CreycloalkylCy-Caalkyl; C,-C.alkoxyCy-Caalkyl; C-Cialkylcarboxy; hydroxyC,-C,alkoxyCs-Csalkyl; hydroxy; hydroxyC,-Csalkyl; phenylC4-Cjalkyl which is optionally substituted by hydroxy, Cs-C.alkoxy, carboxy, C-CaalkoxycarbonylC4-Caalkyl, C+- Caalkoxycarbonyl, cyano; -SO,R'% cyano; -SON(R')R™; -S-R" or -SOR™; or R* and R? or R? and R® denote, together with the carbon atoms to which they are attached, an aromatic or aliphatic carbocyclic group having 5 to 10 ring atoms or an aromatic or aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur; R® is —=CH,-0-C(0)-N(R'})R"™, —CH,-X-C(0)-R", C1-Caalkyl or hydroxyCy-Caalkyl; R’, R® and R® independently are C;-Cjalkyl; R'® and R'! independently are hydrogen, C-Caalkyl; C2-Caalkenyl; Cs-Crcycloalkyl; Cs- C,cycloalkylCy-Caalkyl; Cs-CaalkoxyCy-Caalkyl; C4-Caalkylcarboxy; hydroxyC-CalkoxyCi-
C.alkyl; hydroxy: hydroxyCi-Caialkyl; phenylC,-C,alkyl which is optionally substituted by hydroxy, Cy-C,alkoxy, carboxy, C,-CalkoxycarbonylC4-Cyalkyl, C4-Csalkoxycarbonyl, cyano; or R" and R*' form together an aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur; R'? and R" independently are hydrogen, C;-Caalkyl, Co-Cialkenyl, Cs-Cscycloalkyl, Cs- Cs cycloalkylCy-Ciatkyl, C-CsalkoxyCy-Caalkyl, hydroxyC-CalkoxyC,-Caalkyl, hydroxyC,-
C.alkyl, dihydroxyC4-Csalkyl, Ci-CaalkoxycarbonylCs-Caalkyl, C4-C,alkoxycarbonyl, cyano, - SO,R™. -SON(R)R", -8-R™, -SOR™, -C,-C-alkylene-SO:R", -C-Cs-alkylene-SOR™, - C,-Co-alkylene-NH-SO,R", -C-C-alkylene-CON(R™R"", -CON(R')R"", -Cs-Co-alkylene- C(O)OR" fiuoroalkyl, or R* and R® form a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; !
R™ is NH. Cs-Calkyl-NH-, CCsalkenyl-NH-, Cs-Crcycloalkyl-NH-, C4-CicycloalkylC-Caalkyl- NH-, C,-C,alkoxyC,-Calkyl-NH-, hydroxyCi-CaalkoxyCy-Csalkyl-NH-, hydroxyCy-Caalkyl- NH-, dihydroxyC;-Csalkyl-NH-, C,-C.alkoxycarbonylC4-C,alkyl-NH-, C,-Csalkoxycarbonyl- NH-, _NH-C,-C.-alkylene-CN, -NH-SO:R™®, -NH-SO,N(R")R", -NH-C,-C-alkylene-S-R", -NH- SOR'?, -NH-C;-C,-alkylene-SOR™, -NH-C,-C.-alkylene-SOR'", -NH-C,-C-alkylene-NH- SO,R™®, -NH-C,-C,-alkylene-CON(R')R", -NH-CON(R")R"", -NH-C;-Co-alkylene- C(O)OR'™, -NH-fluoroalkyl, or a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; Xis O or CH; with the proviso that when R' is either halogen, methyl, ethyl, methoxy, trifluromethy! or hydrogen and R?, R®, R* are either hydrogen, methyl or methoxy and R® is hydrogen or methyl, R'? is neither hydrogen, C,-Caalkyl, C-Caalkenyl, hydroxyC;-Cjalkyl, -C4-Ca- alkylene-SO;R", nor -C4-C,-alkylene-SOR"*; in free base or acid addition salt form.
2. A compound of claim 1 selected from the group of 2-ethylcarbamoyloxymethyl-5,7-dimethyl- 3-(2-methylsulfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid ethyl ester and 2- (2-hydroxy-ethylcarbamoyloxymethyl)-5,7-dimethyl-3-(2-methylsulfamoyl-phenyl)-4-oxo-3,4- dihydro-quinazoline-6-carboxylic acid ethyl ester, in free base or acid addition salt form.
3. A process for the production of a compound of formula | or an acid addition salt thereof, comprising (i) for the production of a compound of formula | wherein R® is -CH,-0-C(O)-N(R'*)R"™ and R" is hydrogen, the step of reacting a compound of formula Il
-3g- R? 1 3 7 R R 0 R © C] 9 RN Bee: R* R® R? TN 0) OH wherein R', R?, R®, RY, R®, R’, R®, and R® are as defined in claim 1; with a compound of formula Iii (mn) 0=C=N, R"2 wherein R'is as defined in claim 1; or (ii) alternatively to (i) for the production of a compound of formula | wherein R® is —-CH,-0-C(O)- N(R'?)R'® and R" is hydrogen, the step of reacting a compound of formula IV R? R! rR? , 9 R’ R%q N R* AR R N 0 Oo TY ™ 0) wherein R', R%, R%, R*, R®, R", R®, and R® are as defined in claim 1; with a compound of formula Vv V) 12 HN—R wherein R'? is as defined in claim 1; or
(ili) for the production of a compound of formula | wherein R® = —CH,-X-C(O)}-R" and X = CH, the step of reacting a compound of formula Vi R? R! R® rR’ 9 RNo N~ R* 8 ~ R® R N OH ) 0] wherein R', R, R®, R%, R®, R’, R®, and R’ are as defined in claim 1; with a compound of formula Vii H—R" (vin) wherein R" is as defined in claim 1; or (iv) for the production of a compound of formula | wherein R® = —CH,-X-C(O)-R" and X = O, reacting a compound of formula Vill R? oO R 0 9 Ro N R* 3 Z R® R N Oo Oo hid (Vin) 0) wherein R', R%, R?, RY, R%, R’, R®, and R® are as defined in claim 1; with a compound of formula VII H—R" (Vii) wherein R' is as defined in claim 1; or (v) for the production of a compound of formula | wherein R® is C,-C.alkyl or hydroxyC,-C,alkyl, the step of reacting a compound of formula IX
R? ; R R’ 0 R 4 N R (1X) HO J Re R N° "R wherein R'. R?, R®, R%, R®, R” and R® are as defined in claim 1 and R® is C,-Cqalkyl or hydroxyC,-Caalkyl, with a compound of formula X Y—R® (X) wherein R? is as defined in claim 1 and Y is a leaving group; and recovering the so obtained compound of formula | in free base or in acid addition salt form.
4. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
5. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment or prevention of a disease or condition in which cannabinoid receptor activation plays a role or is implicated.
6. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid salt form, in association with a pharmaceutical carrier or diluent.
7. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment or prevention of a disease or condition in which cannabinoid receptor activation plays a role or is implicated.
8. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment or prevention of a disease or condition in which cannabinoid receptor activation plays a role or is implicated.
9. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment or prevention of ocular disorders selected from the group consisting of glaucoma, normal tension glaucoma and neurodegenerative diseases conditions of the retina and the optic nerve.
10. A method for treating or preventing of ocular disorders selected from the group consisting of : glaucoma, normal tension glaucoma and neurodegenerative diseases conditions of the retina and the optic nerve in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.
11. A combination which comprises (a) a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid salt form and (b) a second drug substance, said second drug substance being for example for use in the treatment and prevention of chronic pain, osteo and rheumatoid arthritis, teno-synovitis and gout, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
12. A method for treating or preventing a disease or condition in which cannabinoid receptor activation plays a role or is implicated, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition sait form.
13. A method of treating a mammal having a disease or condition in which cannabinoid receptor activation plays a role or is implicated comprising administering to the animal a combination which comprises (a) a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid salt form and (b) a second drug substance, said second drug substance being for use in the treatment and prevention of chronic pain, osteo and rheumatoid arthritis, teno-synovitis and gout.
AMENDED CLAIMS [received by the International Bureau on 22 July 2003 (22.07.03); original claims 1-13 replaced by amended claims 1-17)
1. A compound of formula Rr? 7 R! R® Ro N R* A RE 0 R N 6 R wherein ’ R' RZ, R®, R* and R® independently are hydrogen; halogen; C:-Caaltkyl; C-Caalkenyl; Cs C;cycloalkyl; Ca-CreycioalkyiCy-Caalkyl; C,-C.alkoxyC,-Csalkyl; C;-Cqalkylcarboxy; hydroxyC1-CsalkoxyC-C.alkyl; hydroxy; hydroxyCs-Csalkyl: phenylC,-Caalkyl which is optionally substituted by hydroxy, C,-C.alkoxy, carboxy, C.-C alkoxycarbonylG-Caalkyl, G,-Caalkoxycarbonyl, cyano; -SO:R'; cyano; -SO.N(R™)R"; -S-R" or -SOR'"; or R’ and RE? or R? and R® denote, together with the carbon atoms to which they are attached, an aromatic or aliphatic carbocyclic group having 5 to 10 ring atoms or an aromatic or aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur; RS Is ~CH,=0-C(0)-N(R™})R™, =CHz-X-C(0)-R", C-Cialkyl or hydroxyCi-Caalkyl; R’, R® and R® independently are C,-C,alkyl; R™ and R' independently are hydrogen, C,-Calkyl; C-Caalkenyl; C;-C,eycloalkyl; Co C;cycloalkylC,-Caalkyl; C,-C.alkoxyC;-Caalkyl; C-Csalkylearboxy; hydroxyCs-
C.alkoxyCi-Caalkyl; hydroxy; hydroxyC,-C.alkyl; phenyiC:-Caalkyl which Is optionally substituted by hydroxy, Ci-Csalkoxy, carboxy, C:-CaalkoxyzarbonylC,-Caatkyl, C,- Calkoxycarbonyl, cyano; or R' and R'* form together an aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur; R'™ and R" independently are hydrogen, C,-Csalkyl, CCaalkenyl, Cs-Cscycloalkyl, Cs- CscycloalkylCy-Caalkyl, Ci-C.alkoxyC,-Caalki, hydroxyC-C4alkoxyCi-Caalkyl, hydroxyC,-C,alkyl, dihydroxyGC;-Cealkyl, Ci-CealkoxycarboiwiC,-Csalkyl, Cy-
C.alkoxycarbonyl, cyano, -SO;R™, -SO:N(R™R", -8-R"’, SOR", -C-C,-alkylene- SO,RY, -C;-C,-alkylene-SOR™, -C,-C,-alkylene-NH-SO,R", -C,-Cy-alkylene- CON(R™)R", -CON(R™)R", -C;-C-alkylene-C(O)OR™ fiuoroalkyl, or R® and R®form a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; AMENDED SHEET (ARTICLE 19)
£1% is NH, Gy-Caalkyl-NH-, Cz-Caalkenyl-NH-, Gs-Creyoloaligt-Nit- Cy-CroycloalkylCr-Caalkt NH-, C,-C,alkoxyCy-Caalkyl-NH-, hydroxyCi-CalkoxyC:-Caalkyl-NH-, hydroxyCi-Caalkyl NH-, dihydroxyCs-Caalkyl-NH-, C,-CalkoxycarbonylCi-Caalkyl-NH-, C:-
C.alkoxycarbonyl-NH-, i -NH-C,-Ca-alkylene-CN, -NH-SO;R", NH-SON(R¥)R", -NH-C-Ce-alkylene-S-R™, - NH-SOR'™, -NH-C,-C-alkylene-SO:R", _NH-C-Co-alkylena-SOR', -NH-C,-Cy-alkylene- NH-SO.R', NH-C,-Calkylene-CON(R™)R"", NH-CON(R')R", -NH-C,-C.-alkylene- C(O)OR", _NH-fluoroalkyl, or a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; X is O or CHa; with the proviso that when R' is either halogen, methyl, ethyl, methoxy, trifluromethyl or hydrogen and R?, R®, Rt* are either hydrogen, methyl or methoxy and R® is hydrogen or methyl, R'2 is neither hydrogen, Co-Caalkyl, C,-Cqalkenyl, hydroxyCy-Caalkyl, -Ci-Cs- alkylene-SO,R'", nor -C,-C.-alkylene-SOR"; in free base or acid addition salt form.
2. A compound of formula | according to claim 1 wherein R' RZ R?, R* and R® independently are hydrogen; halogen; C-C.alkyl; Co-Calkenyl; Cs C,cycloalkyl; C3-C;cycloalkylC-Caalkyl; C4-C.alkoxyCi-Cqalkyl; C4-Caalkylcarboxy; hydroxyC1-CaalkoxyCy~C.alkyl; hydroxy; hydroxyC1-Cialkyl; phenylC;-Calkyl which is optionally substituted by hydroxy, C;-Caalkoxy, carboxy, Cy-CsalkoxycarbonylC.-Cqalkyl, C,-C.alkoxycarbonyl, cyano; -SOR'; cyano; -SON(R™R"; -S-R" or -SOR™; or R' and R? or RZ and R® denote, together with the carbon atoms to which they are attached, an aromatic or aliphatic carbocyclic group having 5 to 10 ring atoms or an aromatic or aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur; R® is C,-C.alkyl or hydroxyC-C,alkyl; R’, R® and R® independently are C;-Calkyl; R'™ and R" independently are hydrogen, Ci-C.alkyl; CxCaalkeryl; Cs-Creycloalkyt, Cs- C,cycloalkylC,-Cqalkyl; C4-C.alkoxyC,-Caalkyl: C,-Caalkylcarboxy; hydroxyCi-
C.alkoxyCy-Calkyl; hydroxy; hydroxyC,-Caalkyl; phenylC,-Cialkyl which is optionally substituted by hydroxy, C,-C4alkoxy, carboxy, C.-C.alkoxycarbonylCq-Caalkyt, Cy-
C.alkoxycarbonyl, cyano; or R' and R'' form together an aliphatic heterocyclic group AMENDED SHEET (ARTICLE 19)
having 6 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur; R™ and R* Independently are hydrogen, Ci-Caalkyl, Co-Caalkenyl, C,-Creycloalkyl, Ca CycycloalkylC,-Caalkyl, Ci-CealkoxyC,-Caalkyl, hydroxyC-CaalkoxyCy-Caalkyl, hydroxyC;-C.alkyl, dihydroxyC-Csalkyl, C,-CalkoxycarbonylCi-Caalkyl, C-
C.alkoxycarbonyl, cyano, -SC.R', -SON(R™)R™, -S-R™, -SOR", -C-C,-alkylene- SO,RY, -C,-C,-alkylene-SOR", -C-C.-alkylene-NH-SO:R", -C:-C-alkylene- CON(R™R'", -CON(R')R", -C,-Ce-alkylene-C(O)OR™ fiuoroalkyl, or R* and R® form a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; R'is NH, C,-C,alkyi-NH-, C-C.alkenyl-NH-, Cs-Creycloalkyl-NH-, Cs-C;cycioalkylCs-Caalkyl- NH-, CC. alkoxyCi-Caalkyl-NH-, hydroxyCy-CaalkoxyCi-Caalkyl-NH-, hydroxyCi-Caalkyl- NH-, dihydroxyC4-Ciaalkyl-NH-, C4-C.alkoxycarbonylC,-C.eilkyi-NH-, Cs-
C.alkoxycarbonyl-NH-, NH-C,-C.-alkylene-CN, -NH-SO.R™, -NH-SO:N(R*)R", NH-C,-Cs-alkylene-S-R'", - NH-SOR'™, -NH-C1-C.-alkylene-SO,R™, -NH-C,-C.-alkylene-SOR', -NH-Ci-Cy-alkylene- NH-SO,R", -NH-C,-Cy-alkylene-CON(RO)R", -NH-CON(R')R'!, -NH-C,-C.-alkylene- C(O)OR'™, -NH-filuoroalkyl, or a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; X is O or CHy; with the proviso that when R! is either halogen, methyl, ethyl, rnethoxy, trifluromethyl or hydrogen and R?, R®, R* are either hydrogen, methyl or methoxy and R® is hydrogen or methyl, R'? is nelther hydrogen, C,-Caalkyl, C-Cialkenyl, hydroxyC,-Calkyl, -C1-Ce- alkylene-SO,R", nor -C,-C,-alkylene-SOR'™; in free base or acld addition salt form.
3. A compound of formula | according to claim 1, wherein R; represents -SO,NHCH, and the remaining radicals and symbols have the meanings as defined under claim 1.
4. A compound of claim 1 selected from the group of 2-ethylcarbamoyloxymethyl-5,7- dimethyl-3-(2-methylsutfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid ethyl ester and 2-(2-hydroxy-ethylcarbamoyloxymethyl)-5,7-dimethy}-3-(2- methyisulfamoyl-phenyl)-4-oxo-3,4-dihydro-quinazoline-g-carboxylic acid ethyl ester, in free base or acid addition salt form. AMENDED SHEET (ARTICLE 19)
5. A compound of formula 1 w 3 R7 R R RL, N R* . A R® (1) R N RS wherein R' is hydrogen, -CH,C(O)OCHj, -CH,CH.C(O)OCHs, -C(O)N(CHg)2, -C(O)OCH,, cyano, - SO,-1-pyrrolidinyl, -S8O,CHs, -SO,NHCHs, -SO,N(CHy)z, -SON(CH3)CH,COOH, -S-CHy, .SOCH, or R' forms with R? & =NH-CH;-CH;-CHj- or-CH=CH-CH=CH- ring; R?, R°, R* and R® independently are hydrogen; halogen; Gy-Calkyl; C»-Caalkenyl; Cs Creycloalkyl; C3-CroycloalkylCy-Gaalkyl; C-CaalkoxyCy-C.alkyl; Ci-Caalkylcarboxy; hydroxyC;-CsalkoxyCs-Caalkyl; hydroxy; hydroxyCi-Caalkyl; phenylC-Caalkyl which is optionally substituted by hydroxy, Ci-Calkoxy, carboxy, C--CaalkoxycarbonylCy-Caalkyl, C,-Caalkoxycarbonyl, cyano; -SO.R'; cyano; -SO,N(R)R"; -S-R" or -SOR"’ or R’ and R? or R? and R? denote, together with the carbon atoms to which they are attached, an aromatic or aliphatic carbocyclic group having § to 10 ring atoms or an aromatic or aliphatic heterocyclic group having 5 to 10 ring atoms of which one, two or three are hetero atoms selected from nitrogen, oxygen and sulfur; R® is ~CHz-O-C(0)-N(R™)R™, ~CH,-X-C(0)-R", C-Caalky! or lydroxyC1-Caalkyt; R’, R® and R® independently are C-C,alkyl; R' and R"' independently are hydrogen, Cy-Cyalkyl; C.-Cialkenyl; Cs-Crcycloalkyl; Cs- CycycloalkylCy-Caalkyl; C,-CsalkoxyCi-Cqalkyl; C1-Caalkylcarboxy; hydroxyCs-
C.alkoxyC,-Caalkyl; hydroxy; hydroxyCi-Caalkyl; phenylCi-Caalkyl which is optionally substituted by hydroxy, C;-Calkoxy, carboxy, C-CsalkoxysarbonylC,-Csalkyl, Ci-
C.alkoxycatbonyl, cyano; or R' and R'' form together an aliphatic heterocyclic group having 5 to 10 ring atoms of which ane, two or three are hatero atoms selected from nitrogen, oxygen and sulfur; R'? and R™ independently are hydrogen, C;-Caalkyl, Co-Cealkenyl, Cs-C-cycloalkyl, Ca- CicycloalkylCy-Caalkyl, Cy-C.alkoxyCy-Caalkyl, hydroxyCy-C,alkoxyC-Caalkyl, hydroxyC,-Caalkyl, dihydroxyC;-Caalkyl, C,-CaalkoxycarbonylCy-Cqalkyl, Cs- Caalkoxycarbonyl, cyano, -SO,R"™, -SO;N(R')R", -8-R™, -SOR™, -C:-C-alkylene- SO,R™, -C,-C,-alkylens-SOR'®, -C,-C-alkylene-NH-SO:R'", -C1-C,-alkylene- AMENDED SHEET (ARTICLE 19)
CON(R™R", -CON(R'OR", .C4-Ca-alkylene-C(O)OR" fiuoroalkyl, or R® and R®form a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; R™ is NH, C,-C.alkyl-NH-, Co-C.alkenyl-NH-, Cs-Cicycloalkyt-NH-, Cs-CroycloalkylCy-Caalkyl- NH-, Cy-C4alkoxyC1-Caalkyl-NH-, hydroxyC-CaalkoxyCi-Cialkyl-NH-, hydroxyC,-Caalkyl- NH-, dihydroxyC;-Caalkyl-NH-, C,-C.alkoxycarbonylCy-Cazlkyl-NR-, Ci-
C.alkoxycarbonyl-NH-, _NH-Cy-Ca-alkylene-CN, -NH-SO,R™, -NH-SON(R')R", - NH-C-C.-alkylene-S-R", - NH-SOR'™, -NH-C,-C.-alkylene-SOR", NH-C,-C,-alkylerie-SOR", -NH-C,-C,-alkylene- NH-SO,R', -NH-C,-C,-alkylene-CON(R')R', NH-CON(R')R"", -NH-C-C,-alkylene- C(O)OR'™, -NH-fluoroalkyl, or a substituted or unsubstituted aliphatic heterocyclic group having 5 to 10 ring atoms; X is O or CHy; with the proviso that when R' is either halogen, methyl, ethyl, methoxy, trifluromethyt or hydrogen and RZ, R®, R* are either hydrogen, methyl or methoxy and R® is hydrogen or methyl, R'2 is neither hydrogen, Cz-Caalkyl, Co-Caalkenyl, hydroxyCi-Caalkyl, -C-Cs alkylene-SO,R', nor -C,-Ci-aliylene-SOR™; in free base or acid addition salt form.
6. A compound of formula | according to claim 3, wherein R, represents -SO,NHCH; and the remaining radicals and symbols have the meanings as defined under claim 1.
7. A process for the production of a compound of formula | or an acid addition salt thereof, comprising (i) for the production of a compound of formula | wherein R’ is ~CH,-0-C(O)-N(R"})R™ and R' is hydrogen, the step of reacting a compound of formula I! AMENDED SHEET (ARTICLE 19)
Rr?
R! R ]’ 9 Ro N f Rr* R® Sa R (an) OH wherein R', R?, R®, R*, R®, R”, R®, and R’ are as defined in claim 1; with a compound of formula {il (in) 0=C=N__ R wherein R'? is as defined in claim 1; or (ii) alternatively to (i) for the production of a compound of formula | wherein RE is ~CH,-O- C(0)-N(R™)R™ and R™ is hydrogen, the step of reacting a compound of formula IV R? i” Rl R° RY a ~o N"Y, R R® TN R 0 9] Ne ™ (0) wherein R', R?, BR, R*, R%, R’, R®, and R® are as defined in claim 1; with a compound of formula V Vv) HN—R" wherein R" is as defined in claim 1; or AMENDED SHEET (ARTICLE 19)
(ili) for the production of a compound of formula | wherein R¢ = —CH,-X-C(0)-R™ and X = CH,, the step of reacting a compound of formula Vi Rr? 1 3 R’ 3 i 8 Ro N Rr? 8 2 R® R N OH wh 0 wherein R', R%, B®, R, R®, R7, R®, and R” are as defined in claim 1; with a compound of formula Vil H—R" (vin wherein R'" is as defined in claim 1; or (iv) for the production of 8 compound of formula | wherein R® = -CH,X-C(0)-R" and X = O, reacting a compound of formula VIII Rr? 1 3 RQ R 9 Ro N Ré Re Sa R 0) oO hid (Vii) oO wherein R', R%, R®, R%, R®, BR", R®, and R® are as defined In clair 1; with a compound of formula Vii H—R™ (Vit) wherein R" is as defined in claim 1; or (v) for the production of a compound of formula | wherein RC is ©4-C.alkyl or hydroxyCs-
C.alkyl, the step of reacting a compound of formula IX AMENDED SHEET (ARTICLE 19)
14 4) 7 XX d N R 0%) oy 7 R NR wherein R', R2, R?, R%, R®, R” and R°® are as defined in claim 1 and R® is C,-Caalky! or hydroxyC,-Caalkyl, with a compound of formula X Y—R’ xX) wherein R® is as defined in claim 1 and Y is a leaving group; and recovering the so obtained compound of formula | in free base or in acid addition salt form.
8. A compound of claim 1 or 5 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
9. A compound of claim 1 or § in free base or pharmaceutically acceptable acid addition salt form, for use In the treatment or prevention of a disease or condition In which cannabinoid receptor activation plays a role or is implicated.
10. A pharmaceutical composition comprising a compound of cleim 1 or 5 in free base or pharmaceutically acceptable acid salt form, in association with a pharmaceutical carrier or diluent.
11. The use of a compound of claim 1 or 5 in free base or pharmaceutically acceptable acid addition salt form, as a phammaceutical for the treatment or prevention of a disease or condition in which cannabinoid receptor activation plays a role or is implicated.
12. The use of a compound of claim 1 or 5 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment or prevention ota disease or condition in which cannabinoid receptor activation plays a role or is implicated. AMENDED SHEET (ARTICLE 19)
13. The use of a compound of claim 1 or 5 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment or prevention of ocular disorders selected from the group consisting of glaucoma, normal tension glaucoma and neurodegenerative diseases conditions of the retina and the optic nerve.
14. A method for treating or preventing of ocular disorders selected from the group consisting of glaucoma, normal tension glaucoma and neurodegenerative diseases conditions of the retina and the optic nerve in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 or in free base or pharmaceutically acceptable acid addition salt form.
15. A combination which comprises (a) a therapeutically effective amount of a compound of claim 1 or & in free base or pharmaceutically acceptable acid sal! form and (b) a second drug substance, said second drug substance being for example for use in the treatment and prevention of chronic pain, osteo and rheumatoid arthritis, teno-synovitis and gout, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
16. A method for treating or preventing a disease or condition in which cannabinoid receptor activation plays a role or Is implicated, In a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 or 5 in free base or pharmaceutically acceptable acid addition salt forin.
17. A method of treating a mammal having a disease or condition in which cannabinoid receptor activation plays a role or Is implicated comprising administering to the animal & combination which comprises (a) a therapeutically effective amount of a compound of claim 1 or 5 in free base or pharmaceutically acceptable acid salt form and (b) a second drug substance, said second drug substance being for uss in the treztment and prevention of chronic pain, osteo and rheumatoid arthritis, teno-synovitis and gout. AMENDED SHEET (ARTICLE 19)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0202755A GB0202755D0 (en) | 2002-02-06 | 2002-02-06 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200404959B true ZA200404959B (en) | 2006-12-27 |
Family
ID=9930522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200404959A ZA200404959B (en) | 2002-02-06 | 2004-06-23 | Quinazolinone derivatives and their use as CB agonists |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0202755D0 (en) |
ZA (1) | ZA200404959B (en) |
-
2002
- 2002-02-06 GB GB0202755A patent/GB0202755D0/en not_active Ceased
-
2004
- 2004-06-23 ZA ZA200404959A patent/ZA200404959B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB0202755D0 (en) | 2002-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8552015B2 (en) | Quinazolinone derivatives and their use as CB agonists | |
JP6670885B2 (en) | Compositions containing thienopyrimidine and thienopyridine compounds and methods of using them | |
DE60203995T2 (en) | TRIAZOLE BINDINGS AS MMP INHIBITORS | |
CA2502182A1 (en) | Pyrimido[4,5-d]pyrimidine derivatives with anticancer activity | |
RU2449995C2 (en) | Quinazolinone derivatives effective as vanilloid antagonists | |
SK7972000A3 (en) | 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof | |
WO2014104757A1 (en) | 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same | |
JP6467059B2 (en) | Novel FYN kinase inhibitor | |
ES2667847T3 (en) | Substituted pyrimidines useful as EGFR-T790M kinase inhibitors | |
Yu et al. | Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines | |
IL229692A (en) | 4-(1h-pyrrol-3-yl)thiazole derivatives for use as pharmaceutical agents for treating cancer | |
BR112017005113B1 (en) | COMPOUND OF GENERAL FORMULA (I), METHOD FOR PREPARING THE COMPOUND OF GENERAL FORMULA (I), METHOD FOR PREPARING A COMPOUND OF GENERAL FORMULA (IV), PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES RELATED TO ABNORMAL ACTIVITIES OF JAK3 AND/OR JAK1 KINASES , USE OF THE COMPOUND, AND USE OF THE PHARMACEUTICAL COMPOSITION | |
US5574039A (en) | Antiproliferative compounds having nitrogen-containing tricyclic ring systems and phenyl substituents | |
CA2619459A1 (en) | Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | |
CN104955806B (en) | The substituted carboxylic acid derivative as polyprotein xylanase inhibitor for treating osteoarthritis | |
WO2020077944A1 (en) | Purine derivative, preparation method therefor and use thereof | |
ZA200404959B (en) | Quinazolinone derivatives and their use as CB agonists | |
JP2014509637A (en) | Thieno [2,3-d] pyrimidine derivatives and their use to treat arrhythmias | |
WO2015148465A1 (en) | Pyrazole compounds selective for neurotensin 2 receptor | |
AU2007202781B2 (en) | Quinazolinone derivatives and their use as CB agonists | |
CN101448789A (en) | Soluble adenylate cyclase inhibitors | |
JP2023531097A (en) | Salt of Tetrahydroisoquinoline Derivatives, Method for Producing the Same, and Pharmaceutical Application Thereof | |
JP2022504296A (en) | Transcription factor BRN2 inhibitory compounds as therapeutic agents and how to use them | |
KR20100028092A (en) | Hetero bicyclic carboxamide derivatives and their pharmaceutical use and compositions | |
JP2021501765A (en) | Its use as an inhibitor of the bromodomain of xanthine derivatives and BET proteins |